{"study_id": 103508, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the relationship between liver biochemistry parameters, including alanine aminotransferase (ALT), and clinical outcomes in PFIC patients undergoing PEBD surgery.", "results_summary": "The study found that ALT could not discriminate responders from nonresponders for pruritus improvement (AUC 0.74, P=0.06) and did not significantly predict reduced need for liver transplant (AUC 0.62, P=0.46).", "population_specificity": "Patients with progressive familial intrahepatic cholestasis (PFIC) who underwent partial external biliary diversion (PEBD) surgery.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:10.366875+00:00"}
{"study_id": 103498, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19, including the impact on biomarkers like alanine aminotransferase (ALT).", "results_summary": "COVID-19 patients with CVD exhibited elevated levels of ALT, among other injury-related enzymes, indicating potential liver involvement or damage. The study did not focus on alanine supplementation but rather on ALT as a biomarker of disease severity.", "population_specificity": "83 confirmed COVID-19 patients (42 with CVD, 41 without CVD).", "effective_dosage": "Not applicable (study did not involve alanine supplementation).", "study_duration": "Not specified (retrospective analysis of medical records).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:11.253274+00:00"}
{"study_id": 103509, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify T cell receptors (TCRs) recognizing HLA-A for potential immunotherapy targeting Alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC).", "results_summary": "The study identified several TCRs that recognize HLA-A, suggesting potential for T cell-based immunotherapy against HCC, but no direct findings on Alanine were reported.", "population_specificity": "Patients with hepatocellular carcinoma (HCC).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:12.430497+00:00"}
{"study_id": 103503, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the dosimetric accuracy of radiosurgery using alanine pellets as a dosimeter to measure absolute dose in target and brainstem structures.", "results_summary": "Alanine measurements showed median percentage differences to TPS predictions ranging from 0.3% (GammaKnife) to 2.3% (Cyberknife), indicating clinically acceptable agreement across platforms.", "population_specificity": "Anthropomorphic head phantom with target and brainstem structures (not human subjects).", "effective_dosage": "Not specified (used as a dosimeter, not a supplement).", "study_duration": "Single fraction treatment (duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.912089+00:00"}
{"study_id": 103511, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the relationship between liver chemistries (including alanine aminotransferase, ALT) and liver histology in children with NAFLD to identify noninvasive indicators of histological improvement.", "results_summary": "The study found that dynamic changes in serum ALT and GGT were associated with improvements in liver histology, with models showing strong predictive performance (AUROC 0.79-0.91) for histological outcomes, including resolution of borderline zone 1 NASH and fibrosis.", "population_specificity": "146 children with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:15.879925+00:00"}
{"study_id": 103510, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence of metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD) and their association with cardiovascular disease risk factors, including alanine aminotransferase (ALT) levels, among premenopausal and postmenopausal women.", "results_summary": "The study found higher prevalence rates of MetS and NAFLD in postmenopausal women compared to premenopausal women, with abdominal obesity being the most prevalent MetS component. Elevated ALT levels were measured as part of liver function assessments but were not directly linked to outcomes.", "population_specificity": "185 women (88 premenopausal, 97 postmenopausal) receiving healthcare services in Ho Teaching Hospital and Ho Municipal Hospital.", "effective_dosage": "Not specified", "study_duration": "Data collection occurred from November 2018 to January 2020 (cross-sectional study, no intervention duration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:15.904115+00:00"}
{"study_id": 103513, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to identify predictors of severe COVID-19 outcomes, including the role of alanine aminotransferase (ALT) levels in ICU admission.", "results_summary": "Elevated alanine aminotransferase (ALT) levels were significantly associated with ICU admission in COVID-19 patients (P = 0.024), but the study did not assess ALT's therapeutic effects or safety.", "population_specificity": "COVID-19 patients (4,203 individuals across 45 studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:16.936620+00:00"}
{"study_id": 103512, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the impact of liver function on prognosis in HFrEF patients and evaluate the effect of sacubitril/valsartan on liver function measures, including alanine aminotransferase.", "results_summary": "The study found that sacubitril/valsartan significantly improved liver function measures, including a 7.7% reduction in alanine aminotransferase levels compared to enalapril. Total bilirubin was the strongest predictor of adverse outcomes, but alanine aminotransferase improvements were statistically significant.", "population_specificity": "Patients with heart failure with reduced ejection fraction (HFrEF).", "effective_dosage": "Not specified for alanine aminotransferase alone.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:16.998800+00:00"}
{"study_id": 103515, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on preventing HCV infection in organ transplant recipients using ezetimibe and glecaprevir-pibrentasvir.", "results_summary": "The study does not provide any results related to Alanine.", "population_specificity": "HCV-uninfected organ recipients without pre-existing liver disease.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:17.788125+00:00"}
{"study_id": 103514, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine whether suppression of estrogen and mTOR signaling (via letrozole, leuprolide, and everolimus) could have antineoplastic activity in fibrolamellar carcinoma (FLC), not specifically Alanine.", "results_summary": "The study found that neither estrogen deprivation therapy nor mTOR inhibition improved outcomes in FLC, with 0% progression-free survival at 6 months and median overall survival of 12.4 months. Stable disease was observed in 35% of evaluable patients, but no clinical activity was demonstrated.", "population_specificity": "Patients with advanced fibrolamellar carcinoma (FLC), an uncommon malignancy in young people.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:19.651388+00:00"}
{"study_id": 103516, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the benefits of perioperative UTI (urinary trypsin inhibitor) in protecting liver function, as measured by alanine transaminase (ALT) levels, during hepatectomy.", "results_summary": "UTI use was associated with significant improvements in liver function markers (ALT, AST, TBIL) at 1, 3, and 7 days postoperatively, though significant heterogeneity existed among studies.", "population_specificity": "Patients undergoing hepatectomy, primarily those with primary liver carcinoma, liver metastases, or benign liver lesions.", "effective_dosage": "Not specified", "study_duration": "Perioperative (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:21.491682+00:00"}
{"study_id": 103518, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers explored the microbial and functional profile differences in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), including the role of D-alanine pathways.", "results_summary": "The study found that D-alanine pathways were down-regulated in EAC, suggesting a potential metabolic shift. No direct effects of alanine supplementation were assessed.", "population_specificity": "10 BE patients, 6 EAC patients, and 10 controls.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.771351+00:00"}
{"study_id": 103517, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of atezolizumab plus carboplatin and nab-paclitaxel as neoadjuvant treatment for resectable non-small-cell lung cancer, not specifically focused on Alanine.", "results_summary": "The study found that the combination therapy resulted in a high proportion of patients achieving a major pathological response, with manageable treatment-related toxic effects. Increased alanine aminotransferase concentrations were noted as a common treatment-related adverse event in two (7%) patients.", "population_specificity": "Patients aged 18 years or older with resectable stage IB-IIIA non-small-cell lung cancer and a history of smoking exposure.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:23.694996+00:00"}
{"study_id": 103519, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of Curcuma longa L. extract (CLE) on inflammation and muscle damage, including markers like alanine aminotransferase, after a half-marathon race.", "results_summary": "The study found that CLE supplementation increased interleukin-10 levels and reduced myoglobin concentrations post-race, suggesting anti-inflammatory and muscle damage-mitigating effects. However, specific effects on alanine aminotransferase were not highlighted in the results.", "population_specificity": "Healthy, normal-weight male recreational runners.", "effective_dosage": "3 capsules per day (500 mg each).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:24.159371+00:00"}
{"study_id": 103520, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the patterns and clinical significance of liver injury indicators, including alanine aminotransferase (ALT), in COVID-19 patients.", "results_summary": "The study found that ALT elevation followed AST elevation in severe COVID-19 patients, with AST abnormality associated with the highest mortality risk. Liver injury indicators were linked to factors like lymphocyte count decrease, neutrophil count increase, and male gender.", "population_specificity": "5,771 adult patients with COVID-19 pneumonia in Hubei Province.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:24.497561+00:00"}
{"study_id": 103522, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the cumulative risks of hepatocellular carcinoma (HCC) in patients with persistently elevated serum HBV DNA but normal alanine aminotransferase levels compared to inactive carriers.", "results_summary": "The study found that the cumulative HCC risk in the untreated pEDNA group was minimal (1.1% at 5 years, 1.9% at 9 years) and comparable to the IC group. No HCC cases were observed in the subgroup with serum HBV DNA >1,000,000 IU/mL (immune-tolerant phase).", "population_specificity": "Patients with hepatitis B e antigen-positive chronic HBV infection, excluding those with cirrhosis, HCC at enrollment, or prior NUC treatment.", "effective_dosage": "Not specified", "study_duration": "Follow-up from 2006 to 2012 (6 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:27.038662+00:00"}
{"study_id": 103521, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether a prolonged consolidation period (18 months vs. 12 months) of tenofovir disoproxil fumarate (TDF) therapy improved sustained viral suppression in HBeAg-positive chronic hepatitis B (CHB) patients, with a focus on baseline alanine aminotransferase (ALT) as a predictor of HBeAg seroconversion.", "results_summary": "The study found no significant difference in relapse rates between 12-month and 18-month consolidation periods (56.5% vs. 52.2%). However, patients with high baseline HBeAg levels benefited from the longer consolidation period. Baseline ALT >133 U/L significantly predicted HBeAg seroconversion.", "population_specificity": "HBeAg-positive Asian chronic hepatitis B (CHB) patients (n=137, with 46 achieving HBeAg seroconversion).", "effective_dosage": "Not specified (TDF monotherapy dosage not detailed in abstract).", "study_duration": "12-month or 18-month consolidation period post-HBeAg seroconversion, followed by 12-month follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.287642+00:00"}
{"study_id": 103523, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and antiviral activity of multiple doses of JNJ-6379 (a capsid assembly modulator) in patients with chronic HBV infection.", "results_summary": "JNJ-6379 was well tolerated, showed dose-dependent pharmacokinetics, and demonstrated potent antiviral activity, reducing HBV-DNA and HBV-RNA levels in patients. A grade 4 increase in alanine aminotransferase led to discontinuation in one patient.", "population_specificity": "Treatment-na\u00efve patients with chronic HBV infection (HBeAg-positive or -negative) without cirrhosis.", "effective_dosage": "25 mg (with 100 mg loading dose), 75 mg, 150 mg, or 250 mg daily.", "study_duration": "4 weeks of treatment with an 8-week follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.898190+00:00"}
{"study_id": 103524, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the long-term outcomes of Caucasian patients in Western Europe with HBeAg-negative chronic HBV infection, particularly focusing on those with baseline HBV DNA levels \u22652000 IU/mL.", "results_summary": "The study found that 88.6% of patients maintained HBeAg-negative chronic infection status over 12 years, while 6.1% developed chronic active hepatitis (CAH), often linked to immunosuppression. Patients with baseline HBV DNA \u22652000 IU/mL had a higher risk of advanced liver disease, especially if obese.", "population_specificity": "Caucasian individuals with HBeAg-negative chronic HBV infection and persistently normal ALT levels.", "effective_dosage": "Not available", "study_duration": "Mean follow-up of 12 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:29.746272+00:00"}
{"study_id": 103525, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of combining ATRA, ATO, and GO for treating high-risk acute promyelocytic leukemia (APL), not specifically Alanine.", "results_summary": "The study found that the combination therapy was effective (78% 3-year event-free survival) and generally well tolerated, with common toxicities including alanine aminotransferase elevation.", "population_specificity": "High-risk acute promyelocytic leukemia (APL) patients.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up of 3.4 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.788473+00:00"}
{"study_id": 103526, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of nucleos(t)ide analogues, including their impact on alanine aminotransferase (ALT) normalization, in treating chronic hepatitis B (CHB).", "results_summary": "Entecavir was found to be the most potent in normalizing ALT levels among the nucleos(t)ide analogues studied. The analogues did not show higher serious adverse event rates compared to placebo.", "population_specificity": "Adults with chronic hepatitis B (CHB).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.893458+00:00"}
{"study_id": 103528, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the clinical efficacy and safety of traditional Chinese medicine combined with western medicine versus western medicine alone for treating secondary tuberculosis, including its impact on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that combining traditional Chinese and western medicine improved clinical outcomes (e.g., focus absorption rate, sputum smear negative rate) and reduced adverse reactions, including lower elevation rates of ALT compared to western medicine alone.", "population_specificity": "Patients with secondary tuberculosis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.534056+00:00"}
{"study_id": 103527, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of tofogliflozin and glimepiride as add-on therapies on body fat percentage and other metabolic parameters in patients with type 2 diabetes inadequately controlled by metformin plus DPP-4i.", "results_summary": "Tofogliflozin reduced fat mass and alanine aminotransferase levels, while glimepiride increased fat mass. Both drugs similarly reduced HbA1c, but tofogliflozin also lowered uric acid levels.", "population_specificity": "Japanese patients with type 2 diabetes inadequately controlled by metformin plus DPP-4i.", "effective_dosage": "Tofogliflozin (20 mg/day), glimepiride (0.5 mg/day).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.890430+00:00"}
{"study_id": 103529, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To evaluate the efficacy and safety of add-on peginterferon \u03b1-2a to an ongoing nucleos(t)ide analog regimen in chronic hepatitis B patients with HBsAg \u2264 1500 IU/mL.", "results_summary": "The add-on peginterferon \u03b1-2a group showed significantly higher HBsAg clearance (37.4%) and seroconversion rates (29.7%) compared to the monotherapy group (1.9% and 0%, respectively) at week 72.", "population_specificity": "HBeAg-negative chronic hepatitis B patients with HBsAg \u2264 1500 IU/mL after over 1 year of nucleos(t)ide analog therapy.", "effective_dosage": "Not specified", "study_duration": "72 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.780212+00:00"}
{"study_id": 103530, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers investigated the effects of chronic HBV infection duration and HBsAg levels on lymphocyte and HBV-specific T-cell populations, including the role of alanine aminotransferase as a marker.", "results_summary": "The study found that the duration of HBsAg exposure, not its quantity, correlated with anti-HBV immune response levels. HBs-specific T cells were more prevalent in patients under 30 but decreased with age.", "population_specificity": "243 patients with HBV infection (ages 3-75) from the UK and China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.187469+00:00"}
{"study_id": 103531, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining adverse events related to immune checkpoint inhibitors (ICIs), including hepatotoxicity marked by alanine transaminase elevation, but not specifically evaluating alanine as a supplement.", "results_summary": "The abstract reports that ICIs can cause hepatotoxicity, presenting as elevated alanine transaminase or symptomatic hepatitis, and mentions pancreatic injury and other biliary adverse events, but does not discuss alanine supplementation.", "population_specificity": "Patients treated with immune checkpoint inhibitors for various cancers.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:37.898445+00:00"}
{"study_id": 103533, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effect of periodontal treatment on liver damage, P. gingivalis infection, and endotoxemia in patients with NAFLD, with ALT levels as a marker.", "results_summary": "The study does not report specific results regarding Alanine's effects, as it focuses on periodontal treatment outcomes in NAFLD patients.", "population_specificity": "Adult patients (20-85 years old) with NAFLD, ALT \u2265 40 IU/L, and steatosis grade \u2265 1.", "effective_dosage": "Not mentioned", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:38.923646+00:00"}
{"study_id": 103532, "supplement_id": 863, "safety_score": "30", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the completion rate and factors affecting adherence to nine-month latent tuberculosis infection (LTBI) treatment with isoniazid (9H), focusing on hepatotoxicity as measured by alanine aminotransferase levels.", "results_summary": "The study found that hepatotoxicity, both severe and mild, was significantly associated with discontinuation of LTBI treatment, with 44.2% of discontinuations linked to hepatotoxicity. The overall completion rate of the treatment was 62.3%, with most discontinuations occurring in the first three months.", "population_specificity": "Healthcare workers (HCWs) diagnosed with latent tuberculosis infection (LTBI) via QuantiFERON-TB Gold In-Tube tests.", "effective_dosage": "Not specified (study focused on adherence, not dosage variation).", "study_duration": "Nine months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:39.852842+00:00"}
{"study_id": 103534, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine whether plasma levels of pro-inflammatory cytokines (including IL-17, IL-22, IL-23, and IL-33) could predict outcomes in post-cardiac arrest syndrome (PCAS) patients, not specifically to study Alanine.", "results_summary": "The study found elevated plasma creatinine levels in non-survivors compared to survivors, but did not focus on Alanine's effects. Alanine aminotransferase (ALT) levels were mentioned but not analyzed for efficacy or safety.", "population_specificity": "21 patients (10 survivors, 11 non-survivors) who experienced cardiac arrest and successful return of spontaneous circulation (ROSC).", "effective_dosage": "Not available", "study_duration": "Blood samples were taken at baseline (<1h post ROSC), 2 days post ROSC, and 7 days post ROSC.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.062496+00:00"}
{"study_id": 103535, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of guselkumab (an IL-23 inhibitor) in patients with latent tuberculosis infection (LTBI) and moderate-to-severe psoriasis, including monitoring liver function tests like alanine aminotransferase (ALT).", "results_summary": "The study found no cases of active TB in guselkumab-treated patients, with or without LTBI, through 100 weeks. ALT and AST elevations were more common in LTBI+ patients, but overall safety profiles were comparable between LTBI+ and LTBI- groups.", "population_specificity": "Patients with moderate-to-severe psoriasis and latent tuberculosis infection (LTBI).", "effective_dosage": "Not specified for alanine (ALT was monitored, not administered).", "study_duration": "Up to 100 weeks (approximately 2 years).", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.350118+00:00"}
{"study_id": 103536, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a population pharmacokinetic and pharmacodynamic model for inotersen to evaluate exposure-response relationships and optimize dosing in patients with hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN).", "results_summary": "The study found that inotersen's pharmacokinetics were characterized by a two-compartment model, with disease status and lean body mass identified as significant but minor covariates. The analysis suggested that these factors had a small impact on clearance.", "population_specificity": "Patients with hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) and healthy subjects.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.979798+00:00"}
{"study_id": 103538, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of a lifestyle intervention with a mobile app on weight loss in patients with nonalcoholic fatty liver disease (NAFLD), not specifically Alanine.", "results_summary": "The study found that the mobile app-based lifestyle intervention significantly improved weight loss, anthropometric indices, and liver enzyme levels in NAFLD patients compared to the control group. No direct results regarding Alanine were reported.", "population_specificity": "108 adults with NAFLD confirmed by ultrasound and a BMI \u226523 kg/m\u00b2.", "effective_dosage": "Not mentioned", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.634535+00:00"}
{"study_id": 103537, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effect of ursodeoxycholic acid (UDCA) therapy on serum liver function tests, including alanine aminotransferase (ALT).", "results_summary": "The meta-analysis found a significant reduction in alanine aminotransferase (ALT) levels after UDCA treatment, with a weighted mean difference of -15.28 U/L, indicating a hepatoprotective effect.", "population_specificity": "Patients in randomized placebo-controlled trials assessing UDCA's impact on hepatic parameters.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.950973+00:00"}
{"study_id": 103540, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of metformin in improving liver function and body composition in non-diabetic NAFLD patients.", "results_summary": "Metformin significantly reduced BMI and liver enzyme levels (ALT and AST) in non-diabetic NAFLD patients, suggesting improved liver function and body composition. The study highlights the need for further large-scale RCTs to confirm these findings.", "population_specificity": "Non-diabetic patients with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.602882+00:00"}
{"study_id": 103541, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and pharmacokinetics of bentysrepinine (a phenylalanine dipeptide derivative) in healthy Chinese subjects.", "results_summary": "Bentysrepinine was well tolerated with mild and reversible adverse effects, primarily increased ALT and AST levels. No clinically significant changes in ECG, vital signs, or laboratory assessments were observed, and the maximum tolerated dose was not reached.", "population_specificity": "Healthy Chinese subjects", "effective_dosage": "Single doses (50-900 mg) and multiple doses (300 mg and 600 mg)", "study_duration": "Not specified in the abstract", "interactions": "Food may increase bioavailability.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.364608+00:00"}
{"study_id": 103539, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the efficacy, safety, and pharmacokinetics of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML), not specifically Alanine.", "results_summary": "The study found that bosutinib achieved a major molecular response rate of 55.0% at Month 12, with common adverse events including diarrhea and increased alanine aminotransferase. No new safety signals were identified.", "population_specificity": "Japanese patients with newly diagnosed CP CML (Philadelphia chromosome-positive with e13a2/e14a2 transcripts).", "effective_dosage": "400 mg once daily (bosutinib, not Alanine).", "study_duration": "Median follow-up of 16.6 months (range 11.1-21.9).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.366122+00:00"}
{"study_id": 103543, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to highlight the changing epidemiology of HEV infection and its diverse clinical presentations, including extra-hepatic complications, but did not specifically study Alanine.", "results_summary": "The study did not investigate Alanine's effects; it focused on HEV infection's epidemiology, clinical presentations, and extra-hepatic complications.", "population_specificity": "Patients with HEV infection, particularly immunocompromised individuals and those with neurological or renal complications.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:49.469332+00:00"}
{"study_id": 103544, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the clinical efficacy and safety of Qiguiyin (QGY) formula in patients with severe pneumonia, including monitoring alanine aminotransferase levels as a secondary outcome.", "results_summary": "The abstract does not provide specific results regarding alanine aminotransferase levels or the effects of alanine itself, as it focuses on the broader outcomes of the QGY formula trial.", "population_specificity": "Patients with severe pneumonia in China.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.606230+00:00"}
{"study_id": 103542, "supplement_id": 863, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and potential disease-stabilizing effects of leflunomide, which includes monitoring alanine aminotransferase levels as a safety marker, in patients with relapsed/refractory multiple myeloma.", "results_summary": "The study found that leflunomide was generally well-tolerated, with only one case of elevated alanine aminotransferase at the highest dose (60 mg). Nine out of 11 patients achieved stable disease, with two maintaining it for nearly a year or longer.", "population_specificity": "Patients with relapsed/refractory multiple myeloma (\u22653 prior therapies).", "effective_dosage": "20 mg, 40 mg, and 60 mg (dose levels).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.463830+00:00"}
{"study_id": 103546, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of a cranberry supplement (not specifically Alanine) on alanine aminotransferase and insulin levels in patients with NAFLD.", "results_summary": "The study found that both the cranberry supplement and placebo groups showed significant decreases in alanine aminotransferase and insulin levels after 12 weeks, with both groups following a weight loss diet.", "population_specificity": "41 patients with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.657101+00:00"}
{"study_id": 103547, "supplement_id": 863, "safety_score": "70", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether volixibat, an ASBT inhibitor, could improve liver-related outcomes in adults with NASH by reducing liver fat and injury.", "results_summary": "Volixibat did not meet interim or primary efficacy endpoints, showing no significant reduction in liver fat or improvement in liver injury. While it increased bile acid synthesis and reduced cholesterol, these effects did not translate to therapeutic benefits for NASH.", "population_specificity": "Adults with \u22655% steatosis and NASH without cirrhosis (N = 197).", "effective_dosage": "5, 10, or 20 mg once daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:55.119352+00:00"}
{"study_id": 103545, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term influence of direct-acting antiviral agents (DAA) on liver function, including alanine transaminase (ALT) levels, in liver transplant recipients with HCV recurrence.", "results_summary": "The study found that DAA therapy led to significant improvements in ALT and AST levels, with median ALT decreasing from 44.0 IU/mL before therapy to 17 IU/mL at 24 months post-treatment. However, 10 patients did not achieve transaminase normalization by the end of the follow-up period.", "population_specificity": "Liver transplant recipients with HCV recurrence (120 patients).", "effective_dosage": "Not specified for alanine; DAA regimens varied by HCV genotype (e.g., ledipasvir/sofosbuvir with ribavirin for genotype 1).", "study_duration": "Treatment duration varied by regimen; follow-up lasted 24 months post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:55.374206+00:00"}
{"study_id": 103548, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the therapeutic effects of total flavonoids (TFs) from Scabiosa comosa on liver fibrosis in rats and identify potential targets and pathways involved.", "results_summary": "TF treatment significantly reduced ALT, AST, ALP, and hydroxyproline levels, improved fibrotic lesions, and lowered \u03b1SMA and Collagen I expressions. Proteomic analysis revealed downregulation of PPAR and ECM-receptor interaction pathways, with FABP and vWF as key proteins.", "population_specificity": "Wistar rats with CCL4-induced liver fibrosis.", "effective_dosage": "200, 100, and 50 mg/kg TF administered intragastrically.", "study_duration": "10 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.009063+00:00"}
{"study_id": 103551, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare immunological features, including alanine aminotransferase levels, between severe and moderate COVID-19 cases.", "results_summary": "Severe COVID-19 cases showed higher levels of alanine aminotransferase compared to moderate cases, indicating potential liver involvement. The study did not focus on alanine as a supplement but as a biomarker.", "population_specificity": "21 COVID-19 patients (17 male, 4 female) classified as severe (11 cases) or moderate (10 cases).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.450346+00:00"}
{"study_id": 103550, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of regorafenib in Turkish patients with treatment-refractory metastatic colorectal cancer (mCRC), not specifically Alanine.", "results_summary": "The study found that regorafenib had a safety profile consistent with previous trials, with common adverse events including hypophosphataemia, fatigue, and increased alanine aminotransferase (5%). Median progression-free survival was 3.1 months.", "population_specificity": "Adults with mCRC in Turkey who had disease progression after standard therapies.", "effective_dosage": "160 mg once daily for the first 3 weeks of each 4-week cycle.", "study_duration": "Median treatment duration was 2.5 months (range 0.1 to 20.6).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.635596+00:00"}
{"study_id": 103553, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the association between muscle injury (rhabdomyolysis) and elevated alanine aminotransferase levels, and whether this could lead to unnecessary liver investigations.", "results_summary": "The study found that elevated alanine aminotransferase in rhabdomyolysis may not indicate liver injury but rather muscle damage, potentially leading to misdiagnosis and unnecessary liver biopsies. It also discussed pathophysiological mechanisms like oxidative stress that could link muscle injury to actual liver damage.", "population_specificity": "Patients with severe rhabdomyolysis and abnormal liver function tests.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.640742+00:00"}
{"study_id": 103554, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the pharmacokinetics and pharmacodynamics of Ursodeoxycholic acid (UDCA) in overweight subjects with elevated liver enzymes and compare these changes with vitamin E treatment.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "Overweight subjects (body mass index, 25-30 kg/m\u00b2) with elevated liver enzymes.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:59.207959+00:00"}
{"study_id": 103555, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the appetite-suppressant effects of whey proteins and their amino acid composition, including alanine, compared to maltodextrins in obese female subjects.", "results_summary": "Alanine levels were significantly higher with whey proteins than maltodextrins, but its specific role in appetite suppression was not highlighted among the eight amino acids strongly correlated with satiety and GLP-1 stimulation.", "population_specificity": "Obese female subjects", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:02.459689+00:00"}
{"study_id": 103557, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers investigated whether daily folic acid supplementation reduces methotrexate toxicity (including effects on alanine aminotransferase levels) without compromising efficacy in rheumatoid arthritis patients.", "results_summary": "Daily folic acid supplementation significantly improved elevated ALT levels (a marker of liver function) without affecting methotrexate's efficacy or other measured parameters like ESR and CRP.", "population_specificity": "Japanese patients with rheumatoid arthritis treated with methotrexate.", "effective_dosage": "1.25 mg daily folic acid.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.003871+00:00"}
{"study_id": 103556, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and antitumor activity of the novel ALK inhibitor CT-707 in Chinese patients with advanced ALK-rearranged NSCLC.", "results_summary": "CT-707 demonstrated a 77% overall response rate, with partial responses observed in most patients and one complete remission. Common adverse events included diarrhea, elevated liver enzymes, hair loss, and vomiting, with grade 3 diarrhea identified as a dose-limiting toxicity.", "population_specificity": "Chinese patients with advanced ALK-rearranged NSCLC (12 with lung adenocarcinoma, 1 with malignant pleural mesothelioma).", "effective_dosage": "450 to 600 mg orally once daily.", "study_duration": "21 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.311524+00:00"}
{"study_id": 103558, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of D-alanine on emotional processing, cognition, and cortisol levels in healthy volunteers compared to D-serine and placebo.", "results_summary": "D-alanine improved speed in identifying negative facial expressions and categorizing negative self-referential words, with a trend toward better word recall in memory tasks. No significant effects were observed for D-serine or on cortisol levels and working memory.", "population_specificity": "Healthy volunteers", "effective_dosage": "Not specified", "study_duration": "Single dose", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:04.008721+00:00"}
{"study_id": 103560, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers assessed the incidence and risk factors of hepatotoxicity in women of childbearing age initiating EFV-containing regimens, including monitoring alanine aminotransferase levels.", "results_summary": "Severe hepatotoxicity occurred in 2.5% of women after EFV initiation, with liver-related mortality in 3% of those cases. Older age was associated with increased risk of severe hepatotoxicity.", "population_specificity": "ART-naive pregnant women with HIV and CD4 count \u2265\u2009350 cells/\u03bcL and alanine aminotransferase \u2264\u20092.5 the upper limit of normal.", "effective_dosage": "Not specified", "study_duration": "Events occurred between 1 and 132 weeks postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.042974+00:00"}
{"study_id": 103561, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze maternal physiological changes related to a supervised exercise program during pregnancy, not specifically Alanine.", "results_summary": "The study found no significant differences in maternal physiological parameters (e.g., weight, blood glucose, liver enzymes, renal function) between the exercise and control groups.", "population_specificity": "Pregnant women in a single maternity unit in Madrid, Spain.", "effective_dosage": "Not applicable (study focused on exercise, not Alanine).", "study_duration": "From November 2014 to June 2015 (exact intervention duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.310939+00:00"}
{"study_id": 103559, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of adding an SGLT2 inhibitor (including luseogliflozin) to DPP-4 inhibitor therapy on glycemic control and liver function markers, including alanine aminotransferase (ALT), in Japanese type 2 diabetes patients.", "results_summary": "The study found that adding an SGLT2 inhibitor to DPP-4 inhibitor therapy significantly decreased ALT levels, along with other liver function markers (AST and \u03b3-GTP), suggesting improved liver function. The combination therapy also improved glycemic control, body weight, BMI, and lipid profiles.", "population_specificity": "Japanese type 2 diabetes patients with relatively good glycemic control under DPP-4 inhibitor treatment.", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.437558+00:00"}
{"study_id": 103562, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers evaluated the efficacy and safety of dacomitinib versus gefitinib in Japanese patients with EGFR-positive advanced NSCLC, including the effects of dose modifications on adverse events.", "results_summary": "The study found that dacomitinib improved progression-free survival compared to gefitinib but had higher rates of adverse events leading to dose reductions. Dose reductions of dacomitinib reduced the incidence and severity of certain side effects.", "population_specificity": "Japanese patients with EGFR-positive advanced non-small cell lung cancer (NSCLC).", "effective_dosage": "Dacomitinib 45 mg once daily; gefitinib 250 mg once daily.", "study_duration": "28-day cycles (specific total duration not stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.798249+00:00"}
{"study_id": 103563, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between respiratory virus infections and aminotransferase elevation (including alanine aminotransferase, ALT) in infants aged 8-90 days, and to assess the likelihood of primary hepatobiliary disease in this population.", "results_summary": "The study found that ALT elevation was common (22.9%) in infants with respiratory virus infections, but none of the infants with persistent elevation were diagnosed with hepatic disease during follow-up. Parainfluenza virus type 1 was significantly associated with aminotransferase elevation.", "population_specificity": "Infants aged 8-90 days with positive respiratory virus mRT-PCR results.", "effective_dosage": "Not available", "study_duration": "Median follow-up of 10 days (range 3-232 days)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:13.877779+00:00"}
{"study_id": 103569, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential role of alanine in astrocyte swelling and cerebral edema related to hyperammonemia in hepatic encephalopathy.", "results_summary": "The abstract suggests alanine may be involved in astrocyte swelling mechanisms, but no specific findings or effects of alanine are detailed.", "population_specificity": "Patients with liver failure and hepatic encephalopathy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:13.940319+00:00"}
{"study_id": 103564, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of atorvastatin and rosuvastatin on secondary PCI rates and explore risk factors, including Alanine transaminase (ALT), in CHD patients.", "results_summary": "ALT was identified as a risk factor in the RR group (continuous rosuvastatin usage), with a hazard ratio of 1.030. Gene Gpt, encoding a subtype of ALT, showed significantly different expression across statin groups.", "population_specificity": "283 coronary heart disease (CHD) patients.", "effective_dosage": "Not specified", "study_duration": "2011 to 2015 (exact intervention duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:14.082116+00:00"}
{"study_id": 103566, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of gilteritinib monotherapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.", "results_summary": "Gilteritinib demonstrated a statistically significant improvement in overall survival (9.3 months vs. 5.6 months) compared to salvage chemotherapy. Common adverse reactions included increased alanine aminotransferase and other liver enzymes, but the safety profile was considered manageable.", "population_specificity": "Adult patients with relapsed or refractory AML and an FLT3 mutation.", "effective_dosage": "120 mg (three 40 mg tablets) once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:14.495890+00:00"}
{"study_id": 103571, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the molecular aspects of aquaporins, including the role of the conserved asparagine-proline-alanine (NPA) motifs in their structure and function.", "results_summary": "The study found that aquaporins, which contain NPA motifs, selectively transport water and other small molecules, with their cellular functions regulated by posttranslational modifications. AQP2, in particular, plays a significant role in disease conditions related to water balance.", "population_specificity": "Not specified (focus on molecular mechanisms in mammals).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.208661+00:00"}
{"study_id": 103570, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the prevalence of liver injury in patients receiving high-dose acetaminophen and identify associated risk factors, including abnormal alanine aminotransferase levels.", "results_summary": "The study found that 20 of 102 patients analyzed had drug-induced liver injury, with age \u226570 years and serious liver disease being significant risk factors. Abnormal alanine aminotransferase levels were considered in the analysis but were not independently significant in multivariate analysis.", "population_specificity": "Patients treated with acetaminophen \u22651500 mg/d for \u22654 weeks at Ehime University Hospital between April 2011 and December 2014.", "effective_dosage": "\u22651500 mg/d", "study_duration": "\u22654 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.564711+00:00"}
{"study_id": 103572, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of autologous bone marrow stem cell (ABMSC) transplantation in improving liver function and reducing fibrosis in patients with hepatitis B virus-related cirrhosis (HBV-C).", "results_summary": "ABMSC therapy significantly improved liver function (MELD, Child-Pugh scores, bilirubin, albumin, aminotransferases, coagulation) and reduced liver fibrosis markers (hyaluronic acid, laminin, procollagen, collagen IV) in HBV-C patients, with no reported adverse events.", "population_specificity": "Patients with hepatitis B virus-related cirrhosis (HBV-C) (n=662).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.276303+00:00"}
{"study_id": 103567, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of nucleic acid polymers (REP 2139 or REP 2165) combined with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patients with chronic HBV infection, focusing on HBsAg reduction and functional cure.", "results_summary": "The study found that adding NAPs to TDF + pegIFN significantly increased HBsAg loss and seroconversion rates during therapy and functional cure post-therapy, though transaminase increases were more frequent in NAP groups (asymptomatic and normalized later).", "population_specificity": "Patients with chronic HBV infection who were negative for hepatitis B e antigen.", "effective_dosage": "Not specified for alanine (study focused on NAPs, TDF, and pegIFN).", "study_duration": "48 weeks of experimental therapy (TDF + pegIFN + NAPs) following 24 weeks of TDF therapy, plus 48 weeks of treatment-free follow-up.", "interactions": "None mentioned for alanine (study focused on NAP interactions with TDF and pegIFN).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.474686+00:00"}
{"study_id": 103577, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy of SGLT2 inhibitors, including their effect on alanine aminotransferase levels, in treating NAFLD in patients with type 2 diabetes mellitus.", "results_summary": "SGLT2 inhibitors significantly reduced alanine aminotransferase levels and liver fat, along with weight loss, but did not significantly reduce aspartate aminotransferase levels.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:21.978986+00:00"}
{"study_id": 103574, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether Zynamite\u00ae (a mango leaf extract rich in mangiferin) combined with quercetin could facilitate recovery after exercise-induced muscle damage (EIMD).", "results_summary": "Polyphenol supplementation (Zynamite\u00ae + quercetin) attenuated post-competition muscle pain compared to placebo, though competition times were similar between groups.", "population_specificity": "24 women and 33 men matched by sex and 5 km running performance.", "effective_dosage": "140 mg of Zynamite\u00ae combined with 140 mg of quercetin, administered one hour before the competition and every 8 hours thereafter for 24 hours.", "study_duration": "24 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.530411+00:00"}
{"study_id": 103573, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical effectiveness, predictors, and safety of second-generation generic direct-acting antivirals (including alanine aminotransferase as a predictor) in Pakistani chronic hepatitis C patients.", "results_summary": "High sustained virological response (SVR) rates were observed (98% overall), with alanine aminotransferase identified as a statistically significant predictor of SVR. No major adverse events requiring treatment discontinuation were reported.", "population_specificity": "Pakistani chronic hepatitis C patients, predominantly genotype 3 (99.6%), including chronic hepatitis (96%), compensated cirrhosis (3%), and decompensated cirrhosis (1%).", "effective_dosage": "Not specified for alanine aminotransferase.", "study_duration": "Not specified for alanine aminotransferase.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.869933+00:00"}
{"study_id": 103578, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between gender, age, and key biochemical parameters, including alanine aminotransferase (ALT), in HBV patients and healthy controls.", "results_summary": "The study found that ALT levels were associated with HBV diagnosis and that gender significantly affected fibrotouch measurements in both HBV patients and healthy controls.", "population_specificity": "HBV patients and healthy controls.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.133094+00:00"}
{"study_id": 103575, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to explore the efficacy and long-term safety of larotrectinib, a TRK inhibitor, in patients with TRK fusion-positive solid tumours, including its impact on alanine aminotransferase levels.", "results_summary": "The study found that larotrectinib was highly active in TRK fusion-positive solid tumours, with 79% of evaluable patients showing an objective response. Increased alanine aminotransferase was a common but generally mild adverse event, occurring in 3% of patients.", "population_specificity": "Patients aged 1 month to 84 years with locally advanced or metastatic non-CNS primary TRK fusion-positive solid tumours.", "effective_dosage": "Adults: 100 mg twice daily; paediatric patients: 100 mg/m\u00b2 (mostly).", "study_duration": "Continuous 28-day schedule (specific duration not detailed).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.035137+00:00"}
{"study_id": 103581, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) levels in identifying high-risk individuals with chronic hepatitis B for treatment.", "results_summary": "The study highlights that high ALT levels, active viral replication, and advanced fibrosis or cirrhosis are key indicators for treatment in chronic hepatitis B patients, but current guidelines lack consideration of factors like age, gender, and genotype. There is a need for better predictive models to identify high-risk individuals.", "population_specificity": "Individuals with chronic hepatitis B, particularly those with high ALT levels, active viral replication, and advanced fibrosis or cirrhosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.792614+00:00"}
{"study_id": 103579, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of leucine supplementation versus alanine (as a placebo) on muscle mass and strength gains during a 12-week resistance training program in young men.", "results_summary": "Alanine supplementation (as a placebo) resulted in similar increases in muscle strength (leg-press 1RM) and muscle cross-sectional area (mCSA) compared to leucine, with no significant differences between groups. Both groups showed comparable improvements, suggesting alanine did not hinder or enhance training outcomes.", "population_specificity": "Healthy, resistance-trained young men (27 \u00b1 5 years; 78.4 \u00b1 11.6 kg).", "effective_dosage": "2 \u00d7 5 g/day (10 g total daily dose).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:27.382374+00:00"}
{"study_id": 103580, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the combined use of trabectedin and radiotherapy in treating patients with progressing metastatic soft-tissue sarcomas, including evaluating dose-limiting toxic effects and overall response rates.", "results_summary": "The study found dose-limiting toxic effects, including grade 4 alanine aminotransferase level increase in one patient at a higher dose level. The overall response rate in phase 2 was 72% for local assessment and 60% for central assessment.", "population_specificity": "Adult patients with progressing metastatic soft-tissue sarcoma who had undergone at least one previous line of systemic therapy.", "effective_dosage": "Trabectedin at 1.3 mg/m\u00b2 (starting dose), 1.5 mg/m\u00b2 (dose level +1), and 1.1 mg/m\u00b2 (dose level -1), administered every 3 weeks.", "study_duration": "Radiotherapy was administered for 10 days (3 Gy/d), and trabectedin was administered in cycles every 3 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.129501+00:00"}
{"study_id": 103582, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the role of alanine aminotransferase (ALT) as a marker for NASH and advanced fibrosis in patients with Type 2 diabetes and hepatic steatosis.", "results_summary": "Elevated plasma ALT is recommended by the ADA for screening NASH and advanced fibrosis in diabetic patients, as 30-40% may have NASH and 10-15% advanced fibrosis. The abstract does not directly discuss the effects of alanine itself.", "population_specificity": "Patients with Type 2 diabetes and hepatic steatosis or elevated plasma ALT.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:30.064386+00:00"}
{"study_id": 103583, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of antiviral therapy, including monitoring alanine aminotransferase (ALT) levels, in preventing hepatic decompensation and improving outcomes in patients with chronic HBV and cirrhosis.", "results_summary": "The study found that antiviral therapy in chronic HBV patients with cirrhosis can prevent hepatic decompensation, improve liver function scores (CTP and MELD), and reduce the need for liver transplantation and mortality. Patients with co-existent NAFLD and cirrhosis may require additional monitoring or intervention.", "population_specificity": "Patients with chronic hepatitis B virus (HBV) and cirrhosis, including those with co-existent non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.079372+00:00"}
{"study_id": 103584, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of dapagliflozin plus saxagliptin plus metformin versus glimepiride plus metformin on liver fat and adipose tissue volumes in patients with type 2 diabetes.", "results_summary": "The study found that dapagliflozin plus saxagliptin plus metformin significantly reduced liver fat by over 30% and adipose tissue volumes by over 10% compared to glimepiride plus metformin, along with decreased body weight and serum alanine aminotransferase and aspartate aminotransferase levels.", "population_specificity": "82 patients with type 2 diabetes (HbA1c 7.5%-10.5%) on metformin \u22651500 mg/day background.", "effective_dosage": "Dapagliflozin 10 mg/day plus saxagliptin 5 mg/day versus titrated glimepiride 1-6 mg/day.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.670853+00:00"}
{"study_id": 103587, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the clinical significance, mechanisms, and management of hepatitis flares in chronic HBV infection, proposing a working definition for ALT flares.", "results_summary": "The study summarizes existing knowledge on HBV flares, their immunological mechanisms, and clinical scenarios, highlighting unanswered questions to improve understanding and management.", "population_specificity": "Patients with chronic HBV infection.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.499690+00:00"}
{"study_id": 103586, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to determine if a heterogeneous liver ultrasound pattern could identify children with cystic fibrosis (CF) at increased risk for advanced CF liver disease, with a focus on biomarkers like alanine aminotransferase (ALT).", "results_summary": "The study found that children with a heterogeneous liver ultrasound pattern had significantly higher ALT levels and a 9.1-fold increased incidence of developing a nodular pattern, a surrogate for advanced CF liver disease, compared to those with a normal pattern.", "population_specificity": "Children aged 3-12 years with pancreatic insufficient CF, excluding those with known cirrhosis, Burkholderia species infection, or short bowel syndrome.", "effective_dosage": "Not available", "study_duration": "Planned 4-year interim analysis of a 9-year study, with biannual research ultrasound examinations.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.471659+00:00"}
{"study_id": 103588, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the glycemic and pleiotropic effects of SGLT2 inhibitors and DPP4 inhibitors, including changes in alanine aminotransferase (ALT) levels, in real-world type 2 diabetes patients.", "results_summary": "The study found that SGLT2 inhibitors led to greater improvements in ALT levels (-4.1 U/l) compared to DPP4 inhibitors (-0.0 U/l), indicating a beneficial effect on liver health. These changes were statistically significant (P < 0.001).", "population_specificity": "Type 2 diabetes patients in Taiwan initiating SGLT2 inhibitors or DPP4 inhibitors from 2016 to 2017.", "effective_dosage": "Not specified", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:36.317437+00:00"}
{"study_id": 103590, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the hepatotoxicity potential of conventional oral riluzole tablets versus sublingual BHV-0223, a novel formulation of riluzole, in reducing liver toxicity risks.", "results_summary": "The study found that sublingual BHV-0223 reduced the relative risk of ALT elevations >3\u00d7 ULN by 64% compared to oral riluzole tablets, with mechanistic investigations attributing the ALT elevations to oxidative stress. The DILIsym model validated these findings by predicting rates consistent with clinical data.", "population_specificity": "Patients with amyotrophic lateral sclerosis (ALS).", "effective_dosage": "Oral riluzole tablets (50 mg BID) and sublingual BHV-0223 (40 mg BID).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.918243+00:00"}
{"study_id": 103589, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the safety and preliminary antitumor activity of crizotinib plus pembrolizumab as first-line therapy in patients with ALK-rearranged NSCLC, with a focus on dose-limiting toxicities.", "results_summary": "The study found elevated transaminases (ALT and AST) as the most common treatment-related toxicity, with severe increases noted in some patients. The study was terminated early due to slow accrual, preventing definitive conclusions.", "population_specificity": "Patients with ALK-positive advanced non-small cell lung cancer (NSCLC).", "effective_dosage": "Crizotinib 250 mg twice daily and pembrolizumab 200 mg every 3 weeks (DL0); or 3 weeks of crizotinib monotherapy followed by combination therapy (DL-1).", "study_duration": "Cycle duration was 3 weeks, but total study duration was not specified due to early termination.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.017751+00:00"}
{"study_id": 103591, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the safety and efficacy of nivolumab in patients with advanced squamous non-small cell lung cancer (NSCLC), including its effects on alanine aminotransferase (ALT) levels as part of treatment-related adverse events.", "results_summary": "The study found that increased ALT (1%) was among the most frequent grade 3-4 treatment-related adverse events in patients treated with nivolumab. Overall, nivolumab was well tolerated, with safety profiles consistent across populations.", "population_specificity": "Patients with advanced or metastatic squamous NSCLC, including those aged \u226570 and \u226575 years, and those with ECOG PS 2.", "effective_dosage": "Nivolumab 3 mg/kg every 2 weeks.", "study_duration": "Treatment continued until disease progression or unacceptable toxicity, with a minimum follow-up of ~18 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.934317+00:00"}
{"study_id": 103592, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop a non-invasive score (FAST) combining FibroScan, AST, and CAP to identify patients with NASH, elevated NAS, and advanced fibrosis.", "results_summary": "The FAST score demonstrated good discrimination (C-statistic 0.80 in derivation, 0.74-0.95 in validation) and calibration, with high sensitivity (0.90) and specificity (0.90) at defined cutoffs, effectively identifying patients at risk of progressive NASH.", "population_specificity": "Adults (\u226518 years) with suspected NAFLD attending liver clinics in England and international cohorts (France, USA, China, Malaysia, Turkey).", "effective_dosage": "Not applicable (diagnostic score, not a supplement intervention).", "study_duration": "Not applicable (cross-sectional study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.220847+00:00"}
{"study_id": 103593, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of NSAID treatment on muscle protein breakdown (MPB) during immobilization and retraining in older individuals, with a focus on protein remodeling processes.", "results_summary": "MPB was lower during immobilization compared to retraining, but NSAID treatment did not significantly affect MPB rates or the expression of muscle degradation signaling molecules. The findings suggest increased MPB may play a role in muscle protein remodeling during retraining.", "population_specificity": "Older men aged 60-80 years.", "effective_dosage": "2 \u00d7 20 g of whey protein daily (Alanine not specified).", "study_duration": "2 weeks of immobilization followed by 2 weeks of retraining.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.311295+00:00"}
{"study_id": 103594, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of zinc supplementation (not Alanine) on clinical manifestations and anthropometric parameters in overweight/obese non-alcoholic fatty liver patients following a calorie-restricted diet.", "results_summary": "Zinc supplementation significantly increased serum zinc levels and reduced liver enzymes (alanine aminotransferase and \u03b3-glutamyl transpeptidase) but did not significantly affect liver steatosis or fatty liver index. Waist circumference was also reduced in the zinc group.", "population_specificity": "Overweight/obese subjects with non-alcoholic fatty liver disease (NAFLD) confirmed by ultrasonography.", "effective_dosage": "30 mg/day zinc supplement", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.374637+00:00"}
{"study_id": 103595, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the efficacy of near-infrared fluorescence (NIRF) imaging with indocyanine green (ICG) in improving surgical outcomes for hepatolithiasis, including effects on alanine aminotransferase levels.", "results_summary": "NIRF imaging with ICG was associated with lower alanine aminotransferase levels, reduced blood loss, shorter hospitalization, and improved postoperative markers compared to traditional hepatectomy.", "population_specificity": "44 patients with hepatolithiasis undergoing hepatectomy.", "effective_dosage": "Not specified (ICG was injected via peripheral veins).", "study_duration": "Not specified (duration of surgical intervention not detailed).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.696600+00:00"}
{"study_id": 103596, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review unresolved issues related to the definition of the immune-tolerant phase in chronic hepatitis B virus infection and the potential benefit of antiviral treatment.", "results_summary": "The abstract highlights that defining the true immune-tolerant phase requires careful assessment and long-term follow-up, as many patients were previously misclassified. It also notes controversy over the benefit and harm of antiviral treatment for these patients, calling for further large-scale studies.", "population_specificity": "Patients with chronic hepatitis B virus infection in the immune-tolerant phase.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:47.513044+00:00"}
{"study_id": 103598, "supplement_id": 863, "safety_score": "85", "efficacy_score": 78, "quality_score": 72, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of acupoint embedding (alone or combined) for managing NAFLD with abnormal transaminase, focusing on changes in serum alanine aminotransferase (ALT).", "results_summary": "The meta-analysis found that acupoint embedding alone or combined with conventional medications significantly improved ALT levels and other outcomes like aspartate aminotransferase, triglycerides, and total cholesterol, with a satisfactory safety profile.", "population_specificity": "Adult patients with NAFLD and abnormal transaminase confirmed by radiologic evidence.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.886606+00:00"}
{"study_id": 103597, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and efficacy of ropeginterferon alfa-2b (a monopegylated interferon) versus hydroxyurea in patients with polycythaemia vera, focusing on haematological response and disease burden.", "results_summary": "Ropeginterferon alfa-2b showed increasing efficacy over time, with improved haematological responses compared to hydroxyurea at 36 months, though non-inferiority at 12 months was not demonstrated. Safety profiles were comparable, with grade 3/4 adverse events including increased alanine aminotransferase in the ropeginterferon group.", "population_specificity": "Adults (18+) with early-stage polycythaemia vera, no prior cytoreductive treatment or <3 years of hydroxyurea use.", "effective_dosage": "Ropeginterferon alfa-2b (100 \u03bcg subcutaneously every 2 weeks), hydroxyurea (500 mg/day orally).", "study_duration": "3 years (36 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.604946+00:00"}
{"study_id": 103600, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effect of Total Glucosides of Paeony (TGP) on autoimmune liver disease (AILD) patients and experimental autoimmune hepatitis (EAH) in mice, focusing on liver function and hepatocyte apoptosis.", "results_summary": "TGP treatment significantly improved liver function in AILD patients by reducing serum liver enzyme levels and bilirubin. In EAH mice, TGP reduced liver damage, hepatocyte apoptosis, and dendritic cell infiltration, likely via the mitochondrial apoptotic pathway.", "population_specificity": "AILD patients and Con A-induced EAH mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.672132+00:00"}
{"study_id": 103601, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare clinical characteristics and laboratory findings between patients with hemorrhagic fever with renal syndrome (HFRS) complicated by acute pancreatitis (AP) and those with acute biliary pancreatitis (ABP), including differences in alanine aminotransferase levels.", "results_summary": "The study found no statistically significant differences in alanine aminotransferase levels between HFRS complicated by AP and ABP patients, though other laboratory results showed significant differences. Alanine-related outcomes were not a primary focus of the study.", "population_specificity": "Hospitalized patients with HFRS complicated by AP (n=7) and ABP (n=105).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.916553+00:00"}
{"study_id": 103599, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether remote ischemic preconditioning (RIPC) could reduce acute liver injury, as indicated by serum alanine transferase (ALT) levels, following partial hepatectomy in patients with primary hepatocellular carcinoma (HCC).", "results_summary": "The study found no significant difference in median ALT levels at 24 hours post-surgery between the RIPC and control groups. Secondary endpoints also showed no beneficial effects of RIPC on clinical, biochemical, or pathological outcomes.", "population_specificity": "Patients with primary hepatocellular carcinoma undergoing partial hepatectomy.", "effective_dosage": "Four cycles of 5-minute arm cuff inflation/deflation.", "study_duration": "Administered immediately prior to surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.919041+00:00"}
{"study_id": 103602, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether silymarin (Livergol) could prevent increases in liver enzymes (including alanine aminotransferase, ALT) in patients taking isotretinoin.", "results_summary": "The study found that Livergol significantly prevented increases in AST and ALT levels compared to placebo, suggesting it may be an effective treatment for managing isotretinoin-induced liver enzyme elevation. No significant effect was observed for ALP.", "population_specificity": "74 patients with acne taking isotretinoin.", "effective_dosage": "140 mg Livergol capsule once daily.", "study_duration": "30 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.887724+00:00"}
{"study_id": 103585, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of green tea and its catechins, including their impact on alanine transaminase (ALT) levels, in different health populations.", "results_summary": "The study found no significant overall effect of green tea on liver enzymes, including ALT. However, subgroup analyses showed a moderate reduction in ALT levels in participants with NAFLD but a small increase in healthy subjects.", "population_specificity": "Participants included both healthy individuals and those with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.009036+00:00"}
{"study_id": 103603, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to highlight the clinical importance of liver transaminases, particularly alanine aminotransferase (ALT), in diagnosing and managing liver diseases.", "results_summary": "Elevated ALT levels were associated with increased liver-related mortality, and the study outlined the diagnostic and prognostic utility of ALT in various liver conditions, including viral hepatitis, fatty liver disease, and autoimmune disorders.", "population_specificity": "Patients tested for liver diseases (general population, no specific subgroup mentioned).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Hepatotoxic drugs should be excluded when evaluating elevated transaminases.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:55.316864+00:00"}
{"study_id": 103604, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of carnitine supplementation on liver function, lipid profile, body mass index, body weight, and insulin resistance in patients with nonalcoholic fatty liver disease.", "results_summary": "Carnitine supplementation significantly reduced HOMA-IR, AST, ALT, and TG levels but had no significant effect on BMI, body weight, \u03b3GT, TC, HDL-cholesterol, or LDL-cholesterol.", "population_specificity": "Patients with nonalcoholic fatty liver disease (334 individuals, 167 in control and 167 in intervention groups).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:58.015843+00:00"}
{"study_id": 103605, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of the neutral amino acid exchanger ASCT2, which includes alanine transport, in cancer biology and its potential as a molecular target for cancer therapy.", "results_summary": "The study highlights ASCT2's emerging role in cancer biology and the development of ASCT2 inhibitors, though none have achieved sufficient potency or selectivity for clinical use. It also notes structural and functional similarities among SLC1A family members, including ASCT2.", "population_specificity": "Not specified (focus on molecular and cellular mechanisms).", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:59.576167+00:00"}
{"study_id": 103606, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were attempting to determine the efficacy of dual anti-CTLA-4 and anti-PD-1 blockade (ipilimumab plus nivolumab) in patients with nonpancreatic neuroendocrine neoplasms.", "results_summary": "The study found a 44% overall response rate in high-grade neuroendocrine carcinoma patients, but 0% response in low/intermediate grade disease. Toxicity was manageable, with no new safety signals identified.", "population_specificity": "Patients with nonpancreatic neuroendocrine neoplasms (32 eligible participants, 56% with high-grade disease).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:59.866959+00:00"}
{"study_id": 103607, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy of exenatide and insulin glargine in reducing liver fat content and other metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus and nonalcoholic fatty liver disease.", "results_summary": "The study found that both exenatide and insulin glargine reduced liver fat content, but exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB-4, postprandial plasma glucose, and LDL-C.", "population_specificity": "Patients with newly diagnosed type 2 diabetes mellitus and nonalcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.350746+00:00"}
{"study_id": 103610, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate serum biochemical parameters, including venous blood gas (VBG), in adolescents with anorexia nervosa (AN) and correlate them with clinical parameters.", "results_summary": "The study found that respiratory acidosis and increased ferritin were common in AN patients, with respiratory acidosis being the most frequent abnormality. Alanine aminotransferase elevation was observed in 14% of patients at the lowest BMI z-score.", "population_specificity": "Adolescents (87.5% female, mean age 14.9\u00b11.7 years) with anorexia nervosa.", "effective_dosage": "Not mentioned", "study_duration": "Retrospective study spanning from January 2014 to May 2017.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.308993+00:00"}
{"study_id": 103608, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and antitumor activity of BPI-9016M, a tyrosine kinase inhibitor, in Chinese patients with advanced NSCLC, including monitoring alanine transaminase (ALT) elevation as a common adverse event.", "results_summary": "The study found that BPI-9016M had a favorable safety profile with no dose-limiting toxicity observed, though common treatment-related adverse events included ALT elevation (60%). The promising antitumor activity supports further development of the drug.", "population_specificity": "Chinese patients with advanced non-small cell lung cancer (NSCLC).", "effective_dosage": "100 mg to 800 mg once daily (QD dosing, 28 days).", "study_duration": "7 days of pharmacokinetics evaluation followed by continuous administration (28 days).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.611063+00:00"}
{"study_id": 103611, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness of a 12-hour versus a 20-hour acetylcysteine regimen in reducing acetaminophen protein adducts and ALT levels, as indicators of hepatic injury.", "results_summary": "The study found minimal to no acetaminophen protein adducts in both treatment groups, with no significant difference in ALT levels between the 12-hour and 20-hour regimens, supporting the safety of discontinuing acetylcysteine after 12 hours when liver function tests are normal.", "population_specificity": "Subjects enrolled in the NACSTOP trial, likely individuals with acetaminophen overdose.", "effective_dosage": "Abbreviated regimen: 200 mg/kg over 4 hours, then 50 mg/kg over 8 hours; Control regimen: 200 mg/kg over 4 hours, then 100 mg/kg over 16 hours.", "study_duration": "12 hours (abbreviated) vs. 20 hours (control).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.124040+00:00"}
{"study_id": 103614, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "To evaluate the long-term safety and tolerability of ubrogepant, including monitoring alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations, for the acute treatment of migraine.", "results_summary": "Long-term intermittent use of ubrogepant (50 mg and 100 mg) was found to be safe and well-tolerated, with a low incidence of treatment-related adverse events and discontinuations due to adverse events over a 1-year period. The study also noted that ALT/AST elevations \u22653 times the upper limit of normal were adjudicated by an independent panel, suggesting careful monitoring of hepatic safety.", "population_specificity": "Adults with migraine (with or without aura), predominantly female (90%) and white (85%), with an average BMI of 30 kg/m\u00b2.", "effective_dosage": "50 mg or 100 mg, administered as 1 or 2 doses per migraine attack.", "study_duration": "52 weeks (1 year).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:06.256053+00:00"}
{"study_id": 103615, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the performance of different patient-based real-time quality control (PBRTQC) techniques, including moving averages and moving medians, for detecting analytical bias in skewed distributions such as alanine aminotransferase.", "results_summary": "For skewed distributions like alanine aminotransferase, moving averages performed poorly unless a tight upper truncation limit was applied; Box-Cox transformation improved moving average performance and allowed full data utilization. The study confirmed these findings in retrospective detection of a real analytical shift in creatinine and urea.", "population_specificity": "Not specified (patient data used for quality control analysis)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:07.571596+00:00"}
{"study_id": 103616, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers sought to quantify spontaneous liver enzyme abnormalities in patients with cirrhosis due to nonalcoholic steatohepatitis (NASH) to better understand fluctuations that could confound detection of drug-induced liver injury (DILI).", "results_summary": "The study found that spontaneous liver enzyme abnormalities (e.g., ALT, AST) were common in NASH cirrhosis patients, with some reaching 2\u00d7 or 3\u00d7 baseline levels, but rarely meeting DILI suspicion criteria. No patients exhibited elevations consistent with Hy's law.", "population_specificity": "Patients with compensated cirrhosis due to NASH enrolled in clinical trials.", "effective_dosage": "Not specified", "study_duration": "One study followed patients every 13 weeks up to week 57; the other every 4 weeks up to week 120.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.644628+00:00"}
{"study_id": 103618, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of cholic acid therapy in patients with bile acid synthesis disorders (BASD), including its impact on urinary bile acids, liver function, and growth parameters.", "results_summary": "The study found statistically significant improvements in urinary bile acids, height, and body weight, with serum alanine aminotransferase and aspartate aminotransferase levels decreasing in treatment-na\u00efve patients. The most common adverse event was upper respiratory tract infection (17%).", "population_specificity": "Patients with bile acid synthesis disorders (BASD), including those with single enzyme defects (n=41) and Zellweger spectrum disorders (n=12).", "effective_dosage": "10-15 mg\u00b7kg\u00b7day of cholic acid", "study_duration": "Not specified in the abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.363518+00:00"}
{"study_id": 103617, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of higher doses of recombinant human acid-\u03b1 glucosidase (rhGAA) in early-onset Pompe disease, focusing on improvements in motor function, lingual strength, pulmonary function, and biochemical markers.", "results_summary": "Higher rhGAA doses (up to 40 mg/kg weekly) improved gross motor function in 9/10 patients, lingual strength in 6/6 patients, and pulmonary function in 4/11 patients, with significant reductions in biochemical markers. No safety or immunogenicity concerns were observed at higher doses.", "population_specificity": "Infantile-onset Pompe disease (IPD) and late-onset Pompe disease (LOPD) patients with onset before age 5 years.", "effective_dosage": "Up to 40 mg/kg weekly.", "study_duration": "Long-term follow-up of up to 18 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.539371+00:00"}
{"study_id": 103620, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of interleukin-26 (IL-26) in chronic hepatitis B (CHB) and its potential as a biomarker during telbivudine treatment.", "results_summary": "The study found that serum IL-26 levels were elevated in CHB patients and decreased during telbivudine treatment, correlating with reduced HBV DNA and liver enzyme levels. IL-26 may originate from Th17 CD4 cells and serve as a biomarker for CHB prognosis.", "population_specificity": "Chronic hepatitis B (CHB) patients and healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.433209+00:00"}
{"study_id": 103619, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the hepatic safety and pharmacokinetics of ubrogepant, including its effects on serum alanine aminotransferase (ALT) levels in healthy male volunteers.", "results_summary": "Ubrogepant was well-tolerated with minimal changes in ALT levels, similar to placebo, and no participants exhibited ALT levels \u22653\u00d7 the upper limit of normal. The pharmacokinetic profile was linear and suitable for acute migraine treatment.", "population_specificity": "Healthy male volunteers", "effective_dosage": "Single doses (100-400 mg), multiple ascending doses (40-400 mg), and daily 150 mg for 28 days", "study_duration": "Up to 28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.746268+00:00"}
{"study_id": 103621, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the effects of human gamma globulin (HGG) on inflammation targets in children, not specifically Alanine.", "results_summary": "The study found no obvious abnormalities in serum alanine aminotransferase (ALT) levels, but the focus was on HGG's effects, not Alanine.", "population_specificity": "80 children divided into observation and control groups.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.914907+00:00"}
{"study_id": 103622, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and cost of two DAA regimens (sofosbuvir plus daclatasvir vs. ombitasvir, paritaprevir, ritonavir plus ribavirin) for treating chronic hepatitis C virus genotype 4 in Egyptian patients.", "results_summary": "Both regimens showed high sustained virologic response (SVR) rates, with 5.2% relapse in the sofosbuvir-daclatasvir group and 4.1% in the ombitasvir-paritaprevir-ritonavir plus ribavirin group. All patients achieved negative HCV blood levels by the end of treatment.", "population_specificity": "Egyptian patients with chronic hepatitis C virus genotype 4.", "effective_dosage": "Not specified (abstract mentions 12-week regimens but not exact dosages).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:16.298706+00:00"}
{"study_id": 103625, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between the triglyceride glucose (TyG) index and abnormal liver function, as assessed by Alanine Aminotransferase (ALT), in urban and rural Chinese adult populations.", "results_summary": "The study found a linear dose-response relationship between the TyG index and ALT levels, with a 1.222 IU increase in ALT per unit increase in TyG index. The TyG index was also associated with higher odds of abnormal liver function, particularly in urban populations.", "population_specificity": "Urban (Nanjing) and rural (Hefei) Chinese adults.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.368102+00:00"}
{"study_id": 103623, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of an n-3 PUFA-enriched lipid emulsion compared to a standard MCT/LCT lipid emulsion in HPN patients, focusing on liver function parameters including alanine transaminase.", "results_summary": "The study is ongoing, and results are not yet reported in the abstract. The primary endpoint is the change in liver function parameters (including alanine transaminase) from baseline to final visit.", "population_specificity": "Patients with chronic intestinal failure (CIF) requiring home parenteral nutrition (HPN) in European hospitals.", "effective_dosage": "Not specified for alanine; lipid emulsions were administered at 200 mg/ml (Lipidem/Lipoplus\u00ae) or 20% (Lipofundin\u00ae MCT/LCT/Medialipide\u00ae).", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.617298+00:00"}
{"study_id": 103624, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether emricasan, a pan-caspase inhibitor, could improve liver fibrosis without worsening NASH in patients with pre-existing fibrosis.", "results_summary": "Emricasan did not achieve its primary or secondary objectives, showing no significant improvement in liver fibrosis or NASH resolution compared to placebo. However, a small subset of patients with consistent alanine aminotransferase normalization showed potential histologic benefits.", "population_specificity": "Patients with definite NASH and NASH CRN fibrosis stage F1-F3.", "effective_dosage": "5 mg or 50 mg twice daily.", "study_duration": "72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.654527+00:00"}
{"study_id": 103629, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the change in BMI-SDS associated with improved metabolic health markers, including alanine aminotransferase (ALT), in obese children.", "results_summary": "Greater reductions in BMI-SDS were associated with improved ALT levels, but the trend was not statistically significant. No definitive BMI-SDS reduction threshold for improving ALT was identified.", "population_specificity": "Obese children participating in lifestyle interventions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:18.139230+00:00"}
{"study_id": 103627, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the biological and clinical activity of ribociclib plus letrozole in the luminal B subtype of early stage breast cancer, not specifically focused on Alanine.", "results_summary": "Elevated alanine aminotransferase concentrations were reported as a common grade 3-4 adverse event in the ribociclib plus letrozole group (20% of patients), but the study did not assess Alanine's efficacy or primary effects.", "population_specificity": "Postmenopausal women with stage I-IIIA hormone receptor-positive, HER2-negative breast cancer and luminal B subtype.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:19.100329+00:00"}
{"study_id": 103628, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of carnitine supplementation on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.", "results_summary": "Carnitine supplementation significantly reduced serum ALT and AST levels, particularly at dosages of \u2264\u20091000\u2009mg/day or 2000\u2009mg/day for ALT and \u2265\u20092000\u2009mg/day for AST, with effects more pronounced when supplementation lasted at least 3 months in patients with elevated aminotransferase levels.", "population_specificity": "Patients with elevated serum aminotransferase levels.", "effective_dosage": "\u2264\u20091000\u2009mg/day, 2000\u2009mg/day, and >\u20092000\u2009mg/day.", "study_duration": "At least 3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:19.207859+00:00"}
{"study_id": 103626, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated risk factors associated with early mortality in people living with HIV (PLHIV) starting antiretroviral therapy (ART) at low CD4 levels, including the role of elevated alanine aminotransferase (ALT).", "results_summary": "Elevated ALT (\u22655 times its upper limit of normal) was identified as a significant risk factor for early mortality (SHR 6.14; 95% CI 1.62-23.20). The study did not focus on alanine supplementation but highlighted ALT as a biomarker for liver-related risks in PLHIV.", "population_specificity": "People living with HIV (PLHIV) in the Asia-Pacific region initiating ART with CD4 counts <100 cells/\u03bcL.", "effective_dosage": "Not applicable (study did not involve alanine supplementation).", "study_duration": "Follow-up for up to 1 year after ART initiation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:19.211301+00:00"}
{"study_id": 103630, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were assessing the feasibility and safety of a combination regimen including dinutuximab, M-CSF/G-CSF, and teceleukin in Japanese patients with neuroblastoma, not specifically evaluating Alanine.", "results_summary": "The study found that increased alanine aminotransferase was a common adverse event, but it did not evaluate Alanine's effects as a supplement or therapeutic agent.", "population_specificity": "Japanese patients with neuroblastoma who completed induction therapy and high-dose chemotherapy.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "5 consecutive 28-day cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:24.787746+00:00"}
{"study_id": 103631, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the relationship between liver dysfunction, kinetics of liver function tests (including alanine transaminase, ALT), and severity of hepatitis on outcomes in pediatric dengue illness.", "results_summary": "Elevated transaminases (including ALT) were common in dengue cases, with higher levels in severe dengue. Severe hepatitis was associated with organ dysfunction and poor outcomes, including mortality.", "population_specificity": "Hospitalized children (1-12 years) with dengue infection.", "effective_dosage": "Not available", "study_duration": "Serial monitoring during hospitalization (July 2014-July 2015).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.279710+00:00"}
{"study_id": 103632, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the effects of increased calcium consumption from fat-free milk in an energy-restricted diet on metabolic control, including alanine aminotransferase concentrations, in overweight type 2 diabetes mellitus patients.", "results_summary": "The study found that alanine aminotransferase concentrations reduced in the group consuming the calcium-enriched drink (DAIR) compared to the control group (CONT), alongside improvements in other metabolic markers.", "population_specificity": "Overweight type 2 diabetes mellitus patients with low habitual calcium consumption (<600 mg/d).", "effective_dosage": "Not specified for alanine; calcium dosage was 700 mg/d in the DAIR group.", "study_duration": "90 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.844655+00:00"}
{"study_id": 103633, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of HBV vaccines alone or in combination with antiviral drugs in treating chronic hepatitis B (CHB) patients, including the effects on alanine aminotransferase normalization.", "results_summary": "The study found no significant difference between treatment and control groups regarding alanine aminotransferase normalization, HBeAg seroconversion, and HBeAg disappearance. Combination therapy showed higher adverse effects compared to monotherapy.", "population_specificity": "Patients with chronic hepatitis B (CHB) (n = 1956).", "effective_dosage": "Not specified", "study_duration": "12-month follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.993089+00:00"}
{"study_id": 103635, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on the efficacy and safety of DAA-based regimens for HCV genotypes 1, 2, and 3.", "results_summary": "The study does not provide any findings related to Alanine.", "population_specificity": "Patients infected with HCV genotypes 1, 2, and 3, with or without cirrhosis.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.113555+00:00"}
{"study_id": 103636, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and pharmacokinetics of E7090, a selective FGFR1-3 inhibitor, in patients with advanced solid tumors.", "results_summary": "The study assessed dose-limiting toxicity, maximum tolerated dose, and pharmacokinetics of E7090, but no specific results regarding Alanine were reported.", "population_specificity": "Patients with advanced solid tumors in Japan.", "effective_dosage": "Daily oral doses ranging from 1-180 mg.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.671815+00:00"}
{"study_id": 103634, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to describe the epidemiology and clinical characteristics of scrub typhus, including the association of alanine aminotransferase elevation with the disease.", "results_summary": "Elevated alanine aminotransferase levels were significantly associated with scrub typhus cases (aOR: 4.13), indicating liver involvement in the disease. The study did not focus on alanine as a supplement but rather as a biomarker.", "population_specificity": "1,127 patients hospitalized with documented fever in a national tertiary hospital in Hanoi, Vietnam.", "effective_dosage": "Not applicable", "study_duration": "Observational period from June 2012 to May 2013.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.946660+00:00"}
{"study_id": 103637, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate microRNA profiles to differentiate acetaminophen toxicity from other causes of transaminase elevation, including the role of alanine aminotransferase.", "results_summary": "The study identified distinct microRNA elevation patterns in severe acetaminophen toxicity cases, with high peak alanine aminotransferase levels, while less severe cases were harder to distinguish.", "population_specificity": "Adults with presumed acetaminophen toxicity at presentation.", "effective_dosage": "Not available", "study_duration": "Serum samples were collected every 12 hours during hospitalization (duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.018721+00:00"}
{"study_id": 103638, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 78, "quality_score": 85, "study_goal": "The researchers aimed to develop genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate (MTX) in rheumatoid arthritis (RA) patients, with alanine aminotransferase (ALT) as a marker for hepatotoxicity.", "results_summary": "The study found that genetic and clinical models demonstrated moderate diagnostic accuracy for MTX efficacy (AUC 0.844) and high accuracy for hepatotoxicity (AUC 0.906), with ALT elevations used as a hepatotoxicity marker. The combined models improved sensitivity and specificity for both outcomes.", "population_specificity": "166 patients with rheumatoid arthritis treated with MTX.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.051670+00:00"}
{"study_id": 103643, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to identify metabolic biomarkers, including alanine, associated with type 2 diabetes (T2D) risk through a systematic review and meta-analysis.", "results_summary": "The study found that alanine was associated with a higher risk of T2D in prospective studies, suggesting it may serve as a biomarker for increased disease risk.", "population_specificity": "Individuals in studies included in the meta-analysis, with subgroup analyses for Western countries.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.525752+00:00"}
{"study_id": 103642, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare clinical characteristics, prognostic factors, and survival outcomes between malignancy-associated and non-malignancy-associated HLH, with a focus on biomarkers like alanine aminotransferase (ALT).", "results_summary": "The study found that ALT levels differed significantly between malignancy-associated and non-malignancy-associated HLH groups, but the abstract does not report specific effects or outcomes related to alanine supplementation or intervention.", "population_specificity": "Pediatric patients (age < 14 years) with secondary hemophagocytic lymphohistiocytosis (HLH).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective analysis)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.995693+00:00"}
{"study_id": 103639, "supplement_id": 863, "safety_score": "60", "efficacy_score": 55, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ralimetinib in combination with gemcitabine and carboplatin for recurrent platinum-sensitive epithelial ovarian cancer, including monitoring alanine aminotransferase levels as a safety measure.", "results_summary": "The study found a modest improvement in progression-free survival with ralimetinib but no significant difference in overall survival or response rate. Grade 3/4 elevated alanine aminotransferase was more common in the ralimetinib arm, indicating potential liver-related adverse effects.", "population_specificity": "Patients with recurrent platinum-sensitive epithelial ovarian cancer.", "effective_dosage": "200 mg Q12H (ralimetinib).", "study_duration": "Days 1-10 (q21d) in combination with chemotherapy, followed by maintenance ralimetinib.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.110983+00:00"}
{"study_id": 103640, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared the short-term efficacy and safety of laparoscopic precise hepatectomy versus conventional open hepatectomy for treating primary hepatocellular cancer, not specifically focusing on Alanine.", "results_summary": "The study found that laparoscopic precise hepatectomy resulted in less intraoperative blood loss, shorter hospital stays, lower liver function damage (including lower ALT and AST levels), fewer complications, and higher 1-year survival rates compared to conventional open hepatectomy. Alanine aminotransferase (ALT) levels were lower in the experimental group, but the study did not evaluate Alanine as a supplement.", "population_specificity": "90 patients with primary hepatocellular cancer.", "effective_dosage": "Not applicable", "study_duration": "Perioperative period (specific duration not detailed).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.465625+00:00"}
{"study_id": 103644, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare interindividual variability in hepatic fat, adiposity, and liver enzyme markers (including AST/ALT ratio) in children with overweight/obesity undergoing a lifestyle intervention with or without exercise.", "results_summary": "The study found that adding exercise to a lifestyle intervention increased responder rates for hepatic fat, adiposity, and GGT. Improvements in cardiorespiratory fitness were linked to better outcomes in weight and BMI responders.", "population_specificity": "Children aged 9-12 years with overweight/obesity (55% girls).", "effective_dosage": "Not specified (intervention included supervised exercise 3 sessions/week).", "study_duration": "22 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:35.948357+00:00"}
{"study_id": 103647, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the therapeutic potential of a DGAT2 inhibitor (PF-06427878) in reducing hepatic triglycerides and improving NASH-related liver pathology.", "results_summary": "Treatment with PF-06427878 reduced hepatic and plasma triglycerides, decreased lipogenic gene expression in rats, and improved steatosis, ballooning, and fibrosis in a mouse NASH model. Phase 1 human studies were also conducted.", "population_specificity": "Rats on a Western-type diet and a mouse model of NASH; phase 1 human studies mentioned but not detailed.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:36.174628+00:00"}
{"study_id": 103646, "supplement_id": 863, "safety_score": "30", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of INC280 (with or without buparlisib) in patients with recurrent glioblastoma, noting adverse effects such as increased alanine aminotransferase.", "results_summary": "The study found increased alanine aminotransferase as a common adverse event (30.3% in Phase Ib). The combination therapy showed no clear activity, leading to halted enrollment due to limited efficacy.", "population_specificity": "Adult patients with recurrent glioblastoma and PTEN deletion, mutation, or protein loss, plus c-Met amplification.", "effective_dosage": "INC280 300 mg twice daily + buparlisib 80 mg once daily (Phase Ib); INC280 monotherapy in Phase II (dose not specified).", "study_duration": "Not specified in the abstract.", "interactions": "Potential drug-drug interactions noted between INC280 and buparlisib.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:36.868937+00:00"}
{"study_id": 103650, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers compared the effects of propofol-based anesthesia versus desflurane anesthesia on inflammatory responses and clinical outcomes in liver transplant recipients, including alanine aminotransferase levels.", "results_summary": "Propofol-based anesthesia reduced plasma alanine aminotransferase concentrations 24 hours post-transplant and improved graft function recovery compared to desflurane anesthesia.", "population_specificity": "Liver transplant recipients (n=50, randomized into two groups of 25 each).", "effective_dosage": "Not specified", "study_duration": "Perioperative period (specific duration not detailed)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.497593+00:00"}
{"study_id": 103648, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to assess the tolerability and safety of DQTM tablet, which contains Salvia miltiorrhiza salvianolic acids and Panax notoginseng saponins, in healthy volunteers.", "results_summary": "The study found that DQTM tablet was well tolerated at high doses, with no serious adverse events. One subject experienced mildly elevated alanine aminotransferase and aspartate transaminase levels, which resolved spontaneously, and five subjects had a small increase in daily stools.", "population_specificity": "84 healthy volunteers", "effective_dosage": "Single doses up to 5760 mg; multiple doses up to 2160 mg twice daily", "study_duration": "Single dose study and 14 consecutive days for multiple doses", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.932908+00:00"}
{"study_id": 103652, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers aimed to determine whether hepatic/renal lesions from Amanita neoovoidea poisoning were caused by amanitins by analyzing patient samples and mushroom specimens.", "results_summary": "The study identified A. neoovoidea as the cause of acute renal and hepatic failure but found no amatoxins or phallotoxins in the mushrooms. Clinical manifestations included gastrointestinal symptoms, elevated renal and hepatic parameters, and abnormal zymogram levels.", "population_specificity": "Seven patients with acute renal and hepatic failure due to A. neoovoidea ingestion.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.477487+00:00"}
{"study_id": 103649, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine whether perioperative continuation of statin therapy improves early graft patency and safety outcomes in patients undergoing off-pump coronary artery bypass grafting (OPCAB).", "results_summary": "Perioperative statin therapy did not improve early graft patency in OPCAB patients, though a lower risk of graft occlusion was observed among smokers. Continuous statin use was associated with elevated liver function.", "population_specificity": "Patients undergoing off-pump coronary artery bypass grafting (OPCAB) (n=582).", "effective_dosage": "Not specified", "study_duration": "Perioperative period (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.604675+00:00"}
{"study_id": 103651, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if acetaminophen-protein adduct concentrations could predict hepatotoxicity in patients following acetaminophen overdose, regardless of ingestion time.", "results_summary": "The study found that higher initial acetaminophen-protein adduct concentrations were strongly associated with subsequent hepatotoxicity, with an adduct threshold of 0.58 nmol/ml being 100% sensitive and 91% specific for predicting liver injury in patients with initial ALT \u22641,000 U/L.", "population_specificity": "Patients 14 years or older with acetaminophen overdose, regardless of intent or formulation.", "effective_dosage": "Median ingested dose of 20 g (IQR 10-40).", "study_duration": "Serum samples were obtained within the first 24 hours of presentation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.232459+00:00"}
{"study_id": 103654, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the short-term effects of testosterone changes on blood analytes, including alanine aminotransferase, in healthy young men.", "results_summary": "The study found that alanine aminotransferase levels changed inversely with testosterone levels, suggesting a potential link between low testosterone and altered liver enzyme activity. Most results were supported by other studies.", "population_specificity": "Thirty healthy young male volunteers.", "effective_dosage": "Not specified for alanine aminotransferase (testosterone undecanoate dosage: 1000 mg).", "study_duration": "3 weeks post-castration, followed by 2 weeks of testosterone replacement.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.312269+00:00"}
{"study_id": 103655, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether adjunctive lidocaine reduces adverse effects in pediatric patients sedated with ketamine, including effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that ALT levels rose more in patients treated with ketamine alone compared to those treated with a ketamine-lidocaine complex. The ketamine-lidocaine combination also reduced adverse reactions and altered ketamine pharmacokinetics.", "population_specificity": "Pediatric patients requiring anesthesia (n=586).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Ketamine-lidocaine complex altered ketamine pharmacokinetics (prolonged elimination half-life, increased AUC, decreased plasma clearance).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:45.353669+00:00"}
{"study_id": 103653, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether reducing lipid dose by 50% and switching to a fish oil-based lipid emulsion (FO LE) was more effective and safer in lowering plasma phytosterols (PS) and \u03b3-glutamyl transferase (GGT) compared to reducing lipid dose while maintaining an olive/soybean-based lipid emulsion (O/S LE).", "results_summary": "The study found that the FO LE group showed significantly lower GGT, alkaline phosphatase (AP), and phytosterol levels compared to the O/S LE group, with a more pronounced decrease in alanine transaminase (ALT). No differences were observed in total bilirubin (BIL).", "population_specificity": "Patients with normal initial GGT who developed elevated GGT after at least one week of parenteral nutrition (PN) containing O/S-based LE.", "effective_dosage": "Lipid dose reduced from 0.8 g/kg/day to 0.4 g/kg/day.", "study_duration": "7 days post-randomization.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:45.977022+00:00"}
{"study_id": 103656, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus on treatment endpoints for chronic HBV, including the role of alanine aminotransferase normalization as an intermediate goal in HDV coinfection.", "results_summary": "The study concluded that sustained HBsAg loss with undetectable HBV DNA is the primary goal for HBV functional cure, while alanine aminotransferase normalization alongside HDV RNA suppression is an intermediate goal for HDV coinfection.", "population_specificity": "Patients with HBeAg-positive or negative chronic hepatitis, treatment-na\u00efve or virally suppressed on nucleos(t)ide analogues, and those with HDV coinfection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:49.402823+00:00"}
{"study_id": 103658, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between cytokine levels (particularly IL-10) and postpartum ALT abnormalities in HBeAg-positive chronic hepatitis B patients.", "results_summary": "The study found that CHB patients with postpartum ALT abnormalities (>2ULN) had higher IL-10 levels compared to controls, and abnormal IL-10 levels were an independent risk factor for elevated ALT. No differences were observed in other cytokines, cortisol, or regulatory T cells among the groups.", "population_specificity": "Pregnant HBeAg-positive chronic hepatitis B patients.", "effective_dosage": "Not available", "study_duration": "Postpartum 6 to 8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.097232+00:00"}
{"study_id": 103657, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the real-world clinical outcomes of pazopanib (PAZ) after immuno-oncology (IO) therapy in patients with advanced renal cell carcinoma (aRCC), not specifically Alanine.", "results_summary": "The study found that PAZ after IO therapy had a median duration of therapy of 13.4 months, median progression-free survival of 13.5 months, and overall survival rates of 93% at 6 months and 89% at 12 months. Adverse events were reported in 42% of patients, with fatigue and diarrhea being the most common.", "population_specificity": "Patients aged \u226518 years with clear cell aRCC who initiated PAZ after IO therapy.", "effective_dosage": "Not specified", "study_duration": "Median duration of PAZ therapy was 13.4 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.521217+00:00"}
{"study_id": 103659, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study evaluated the antitumor activity and safety of pembrolizumab in patients with metastatic MSI-H/dMMR colorectal cancer, not specifically Alanine.", "results_summary": "The study found pembrolizumab effective with manageable safety, but Alanine was only mentioned as an adverse event (increased alanine aminotransferase) in a few patients, not as a primary focus.", "population_specificity": "Patients with metastatic MSI-H/dMMR colorectal cancer treated with prior lines of therapy.", "effective_dosage": "Not applicable (study focused on pembrolizumab, not Alanine).", "study_duration": "Up to 2 years (pembrolizumab administration).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.620415+00:00"}
{"study_id": 103661, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess how isocaloric substitutions of dietary sugars (including fructose, glucose, sucrose) with other carbohydrates (e.g., starch) affect cardiometabolic risk factors, including alanine transaminase (ALT).", "results_summary": "The study found no significant effects on ALT levels when substituting dietary sugars with other carbohydrates. The certainty of evidence was rated very low to moderate.", "population_specificity": "1,383 participants from 38 randomized controlled trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.915078+00:00"}
{"study_id": 103663, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness and safety of statins in children with heterozygous familial hypercholesterolemia, not specifically Alanine.", "results_summary": "The study found that statins reduced LDL cholesterol levels in children with familial hypercholesterolemia, with few or no safety issues identified in the short term. Alanine aminotransferase levels showed little or no difference between statin and placebo groups.", "population_specificity": "Children up to 18 years old with heterozygous familial hypercholesterolemia.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median 24 weeks (range from six weeks to two years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:54.166650+00:00"}
{"study_id": 103662, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine whether low baseline BMI and CD4 cell count are risk factors for antiretroviral drug-related liver injury (ARLI) in HIV-infected patients, with ALT (Alanine aminotransferase) as a biomarker.", "results_summary": "The study found that low baseline BMI (<18.5 kg/m\u00b2) significantly increased the risk of ARLI (5.53-fold), while low baseline CD4 cell count (<200 cells/\u00b5L) did not. ALT testing was suggested for early ARLI detection, particularly in patients with low BMI.", "population_specificity": "75 HIV-AIDS patients receiving ARV therapy (tenofovir, lamivudine, efavirenz) at a hospital outpatient clinic.", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:54.791702+00:00"}
{"study_id": 103660, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, safety, and antiviral activity of ABI-H0731, an investigational inhibitor of the HBV core protein, in healthy adults and individuals with chronic HBV infection.", "results_summary": "The study found that ABI-H0731 was rapidly absorbed with a plasma half-life supportive of once-daily dosing, and it demonstrated dose-dependent decreases in serum HBV DNA and RNA concentrations. Adverse events were mostly mild or moderate, with only one severe case reported at the highest dose.", "population_specificity": "Healthy adults (18-65 years) and adults with chronic HBV infection (HBeAg-positive or HBeAg-negative).", "effective_dosage": "Single doses of 100, 300, 600, or 1000 mg; once-daily or twice-daily doses of 800 mg for 7 days (healthy volunteers); once-daily doses of 100, 200, 300, or 400 mg for 28 days (HBV-infected participants).", "study_duration": "7 days for healthy volunteers, 28 days for HBV-infected participants.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.108287+00:00"}
{"study_id": 103664, "supplement_id": 863, "safety_score": "20", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of neoadjuvant buparlisib versus placebo for breast cancer, including its impact on alanine aminotransferase (ALT) levels.", "results_summary": "Neoadjuvant buparlisib significantly increased grade 3/4 adverse events, including elevated ALT levels, but showed efficacy in reducing progressive disease and improving stable disease in breast cancer patients. No notable influence was observed on overall response rate or clinical benefit rate.", "population_specificity": "Breast cancer patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:56.963996+00:00"}
{"study_id": 103665, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy of caspofungin vs fluconazole prophylaxis against invasive fungal disease in pediatric and young adult patients with acute myeloid leukemia, not specifically to evaluate alanine.", "results_summary": "The study found that caspofungin resulted in a significantly lower incidence of invasive fungal disease compared to fluconazole, with no significant differences in empirical antifungal therapy or overall survival. Elevated alanine transaminase was noted as a common toxicity in both groups.", "population_specificity": "Children, adolescents, and young adults (aged 3 months to 30 years) with newly diagnosed, relapsed, or secondary acute myeloid leukemia.", "effective_dosage": "Not specified for alanine.", "study_duration": "Prophylaxis was administered during the neutropenic period following each chemotherapy cycle.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.021836+00:00"}
{"study_id": 103668, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of hepatocyte-specific FoxM1 in liver inflammation and its link to hepatocellular carcinoma (HCC), not specifically focusing on Alanine.", "results_summary": "The study found that hepatocyte-specific FoxM1 overexpression induced liver inflammation, elevated serum alanine aminotransferase levels, and led to spontaneous HCC development in transgenic mice. Inhibition of FoxM1 reduced liver inflammation in injury models.", "population_specificity": "Hepatocyte-specific FoxM1 conditional transgenic mice.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Up to 12 months for HCC development.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.067475+00:00"}
{"study_id": 103666, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of whole-grain consumption on hepatic steatosis and liver enzymes, including alanine aminotransferase, in patients with NAFLD.", "results_summary": "The study found that whole-grain consumption significantly reduced serum alanine aminotransferase levels and improved NAFLD grades in the intervention group compared to the control group. No significant differences were observed in lipid profile, glycaemic status, or anthropometric measurements after adjustments.", "population_specificity": "112 patients with NAFLD (mean age 43 years, BMI 32.2 kg/m\u00b2).", "effective_dosage": "At least half of daily cereal servings from whole-grain foods.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.308438+00:00"}
{"study_id": 103667, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to compare the effects of walnuts, fish, and their combination on cardiovascular risk factors, including alanine aminotransferase (ALT) levels, in overweight or obese women undergoing weight loss.", "results_summary": "The study found a significant reduction in ALT levels (-6.4 \u00b1 0.9 mg/dL, P < 0.001) in the group consuming both fish and walnuts, indicating improved liver function. The combination was more effective than fish or walnuts alone in reducing ALT and other cardiovascular risk factors.", "population_specificity": "Overweight or obese women undergoing weight loss.", "effective_dosage": "Fish (300 g/week), walnuts (18 walnuts/week), or a combination (150 g fish + 9 walnuts/week).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.797909+00:00"}
{"study_id": 103669, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate HAO472, an L-alanine-(14-oridonin) ester trifluoroacetate, as a potential treatment for acute myelogenous leukemia.", "results_summary": "The study explored the synthetic, physiological, and pharmacological properties of oridonin derivatives, highlighting HAO472's potential as a new anticancer drug candidate. No specific efficacy results for Alanine were detailed in the abstract.", "population_specificity": "Patients with acute myelogenous leukemia (specific details not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.130889+00:00"}
{"study_id": 103671, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of glecaprevir/pibrentasvir for 6 weeks in people with acute and recent HCV infection, focusing on sustained virologic response.", "results_summary": "Glecaprevir/pibrentasvir for 6 weeks was highly effective in achieving sustained virologic response at 12 weeks posttreatment (SVR12) among individuals with acute and recent HCV infection, supporting further evaluation of shortened-duration therapy.", "population_specificity": "Adults with recent HCV infection (duration < 12 months), predominantly men who have sex with men (90%), including HIV-positive individuals (77%) and those with a history of injection drug use (47%).", "effective_dosage": "300/120 mg daily", "study_duration": "6 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.201987+00:00"}
{"study_id": 103672, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of vitamin E (alpha-tocopherol) in treating nonalcoholic steatohepatitis (NASH) in HIV-infected patients, focusing on changes in alanine aminotransferase (ALT), CAP scores, and CK-18 levels.", "results_summary": "Vitamin E treatment for 24 weeks significantly improved ALT levels, CAP scores, and CK-18 levels, indicating reduced liver damage and apoptosis. No serious adverse events were reported, and the treatment was well tolerated.", "population_specificity": "HIV mono-infected patients without significant alcohol intake or viral hepatitis coinfection, diagnosed with NASH.", "effective_dosage": "800 IU daily of oral vitamin E (alpha-tocopherol).", "study_duration": "24 weeks of treatment, followed by 24 weeks of post-discontinuation follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.274066+00:00"}
{"study_id": 103673, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of an 8-week glecaprevir/pibrentasvir regimen in HCV treatment-na\u00efve patients with APRI \u2264\u20091 and no prior evidence of cirrhosis, not specifically focusing on Alanine.", "results_summary": "The study found high efficacy (SVR12 rates of 96.5-100%) and good tolerability of glecaprevir/pibrentasvir in HCV treatment-na\u00efve patients, with no virologic failures and low rates of serious adverse events (2%). Alanine aminotransferase (ALT) levels showed no grade 3 or higher abnormalities.", "population_specificity": "HCV treatment-na\u00efve adults with chronic HCV genotypes 1-6 infection, APRI\u2009\u2264\u20091, and no prior evidence of cirrhosis.", "effective_dosage": "Not specified for Alanine.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:07.042837+00:00"}
{"study_id": 103676, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to test the effect of TVB-2640, a fatty acid synthase inhibitor, on reducing hepatic fat and other biomarkers of de novo lipogenesis in obese men at risk for NAFLD.", "results_summary": "The study found that TVB-2640 reduced hepatic fat and other biomarkers of de novo lipogenesis, supporting its therapeutic potential for NAFLD and nonalcoholic steatohepatitis.", "population_specificity": "Obese men (mean age 42 \u00b1 2 years, BMI 37.4 \u00b1 1.2 kg/m\u00b2) with metabolic abnormalities putting them at risk for NAFLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.920594+00:00"}
{"study_id": 103674, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify clinical and epidemiological factors associated with death in hospitalized yellow fever patients, including the role of elevated alanine aminotransferase (ALT).", "results_summary": "Elevated ALT (>4,000 U/L) was a significant predictor of higher chance of death in yellow fever patients, alongside changes in renal excretion. The study did not assess Alanine as a supplement but focused on ALT as a biomarker of liver damage.", "population_specificity": "Hospitalized patients with confirmed yellow fever in Rio de Janeiro, Brazil (86.5% male, median age 49.5 years, 40.4% rural workers).", "effective_dosage": "Not applicable (ALT levels were measured, not supplemented).", "study_duration": "Not applicable (retrospective observational study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.635005+00:00"}
{"study_id": 103675, "supplement_id": 863, "safety_score": "40", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers assessed the safety and activity of ceritinib plus nivolumab in patients with ALK-rearranged NSCLC, focusing on PD-L1 expression and adverse events, including increased alanine aminotransferase levels.", "results_summary": "The study found that ceritinib plus nivolumab had activity, with overall response rates higher in ALK inhibitor-naive patients and those positive for PD-L1. Adverse events, including increased alanine aminotransferase levels (25%), were common, with higher toxicity in the 450-mg cohort.", "population_specificity": "Patients with stage IIIB or IV ALK-rearranged NSCLC, previously treated or treatment-naive.", "effective_dosage": "Nivolumab (3 mg/kg intravenously every 2 weeks) plus ceritinib (450 mg or 300 mg daily with a low-fat meal).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.149300+00:00"}
{"study_id": 103677, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of ensartinib, an ALK inhibitor, in ALK-positive NSCLC patients who had failed crizotinib therapy, including those with brain metastases.", "results_summary": "Ensartinib showed activity in crizotinib-refractory ALK-positive NSCLC patients, with 52% achieving an objective response and 70% in those with measurable brain metastases. Adverse events were common but mostly mild (grade 1 or 2), including increased alanine aminotransferase concentrations in 46% of patients.", "population_specificity": "Adults (\u226518 years) with stage IIIb/IV ALK-positive NSCLC who progressed on crizotinib therapy, including those with asymptomatic CNS metastases.", "effective_dosage": "225 mg orally once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.113599+00:00"}
{"study_id": 103679, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical effects of ultrasound-guided microwave ablation versus conventional surgical excision in patients with primary hepatic carcinoma, including impacts on hepatic function markers like alanine aminotransferase.", "results_summary": "The study found that ultrasound-guided microwave ablation resulted in higher treatment effectiveness, lower complication rates, and improved hepatic function (lower alanine aminotransferase and aspartate transaminase levels) compared to conventional surgery.", "population_specificity": "94 patients with primary hepatic carcinoma admitted to a hospital between August 2014 and November 2016.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.170970+00:00"}
{"study_id": 103678, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to understand the clinical features, treatment, and outcomes of macrophage activation syndrome (MAS) in pediatric rheumatology patients, including the role of biomarkers like alanine aminotransferase (ALT).", "results_summary": "The study found no significant difference in alanine aminotransferase (ALT) levels at the onset of MAS compared to pre-MAS stages in systemic juvenile idiopathic arthritis (SJIA) patients, suggesting ALT may not be a predictive marker for MAS in this context.", "population_specificity": "Pediatric patients with macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (SJIA), Kawasaki disease (KD), or connective tissue disease (CTD).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.602329+00:00"}
{"study_id": 103680, "supplement_id": 863, "safety_score": "30", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers assessed the safety of simvastatin (at two doses) combined with rifaximin in patients with decompensated cirrhosis, focusing on liver and muscle toxicity.", "results_summary": "Simvastatin 40 mg/day plus rifaximin caused significant increases in AST, ALT, and creatine kinase, leading to treatment withdrawal in many patients, while the 20 mg/day dose showed no significant differences compared to placebo.", "population_specificity": "Patients with decompensated cirrhosis and moderate-to-severe liver failure (Child-Pugh class B or C).", "effective_dosage": "Simvastatin 40 mg/day or 20 mg/day plus rifaximin 1200 mg/day.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.796018+00:00"}
{"study_id": 103681, "supplement_id": 863, "safety_score": "80", "efficacy_score": 98, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in treating chronic hepatitis C virus (HCV) genotype 1 infection, with a focus on alanine transaminase levels as a safety marker.", "results_summary": "The study found that EBR/GZR was highly effective, with a 98% sustained virologic response rate (SVR12), but three participants discontinued due to elevated alanine transaminase levels exceeding 10 times the upper limit of normal. Most side effects were mild.", "population_specificity": "Patients with chronic HCV genotype 1 infection in Taiwan.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Treatment period from June 2017 to April 2018 (exact duration per patient not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:16.073453+00:00"}
{"study_id": 103683, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine the frequency of abnormal findings in neonates with congenital CMV infection who had a normal physical examination, including evaluating serum alanine aminotransferase (ALT) concentrations.", "results_summary": "Among neonates with congenital CMV infection and a normal physical exam, 39% had elevated ALT concentrations, indicating potential liver involvement. The study did not assess Alanine's efficacy or safety as a supplement.", "population_specificity": "Neonates with congenital CMV infection and a normal physical examination.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.894858+00:00"}
{"study_id": 103686, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers aimed to report cases of autoimmune hepatitis (AIH) in HIV-infected patients with restored immune status.", "results_summary": "The study identified 13 HIV-infected patients who developed AIH after achieving stable viral suppression and immune restoration. It highlights the emergence of AIH in this population.", "population_specificity": "HIV-infected patients (5 males, 8 females) with stable viral suppression and median CD4+ counts of 557 cells/\u00d710.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.362096+00:00"}
{"study_id": 103684, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the evolution of HBV activity in HBeAg-negative, HIV/HBV co-infected patients not on ART, focusing on fluctuations in HBV DNA and ALT levels.", "results_summary": "The study found that 48% of patients fluctuated between 'infection' and 'hepatitis' phases, with wider dispersion in HBV DNA and ALT levels linked to higher baseline HIV RNA and HBV DNA levels.", "population_specificity": "HBeAg-negative, HIV/HBV co-infected patients from sub-Saharan Africa not indicated for ART.", "effective_dosage": "Not mentioned", "study_duration": "Median 25 months (IQR 19-31)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.620340+00:00"}
{"study_id": 103682, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the efficacy and safety of ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC, not specifically focused on Alanine.", "results_summary": "The study found that ramucirumab plus erlotinib significantly improved progression-free survival compared to placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Increased alanine aminotransferase was noted as a common adverse event in the placebo plus erlotinib group, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18 or older (20 or older in Japan and Taiwan) with stage IV NSCLC, EGFR exon 19 deletion or exon 21 substitution mutations, and no CNS metastases.", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "Median follow-up was 20.7 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.254500+00:00"}
{"study_id": 103687, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in Chinese hepatocellular carcinoma (HCC) patients and identify prognostic factors for treatment response and survival.", "results_summary": "The study reported a complete response rate of 22.9%, partial response rate of 60.7%, and objective response rate of 83.6%. The mean progression-free survival was 362 days, and the mean overall survival was 380 days.", "population_specificity": "Chinese hepatocellular carcinoma (HCC) patients (n=275).", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.660528+00:00"}
{"study_id": 103689, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to systematically assess how definitions and outcome measures are defined in therapeutic trials of children with chronic intestinal failure (IF).", "results_summary": "The study found a lack of uniform definitions for chronic IF in pediatric studies, with only 23% of included studies reporting any definition. Outcome measures were highly heterogeneous, with mortality, liver enzymes (including alanine aminotransferase), and growth being the most frequently reported.", "population_specificity": "Children with chronic intestinal failure.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.708068+00:00"}
{"study_id": 103690, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy and safety of levoketoconazole, not Alanine, in patients with endogenous Cushing's syndrome.", "results_summary": "The study found that levoketoconazole led to sustained improvements in urinary free cortisol, with 31% of patients achieving mUFC normalisation. Adverse events included nausea, headache, and reversible alanine aminotransferase increases in 11% of patients.", "population_specificity": "Adults (\u226518 years) with confirmed Cushing's syndrome and elevated urinary free cortisol levels.", "effective_dosage": "150 mg twice daily, titrated up to 600 mg twice daily.", "study_duration": "2-21 week dose-titration phase followed by a 6-month maintenance phase.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:22.478745+00:00"}
{"study_id": 103691, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the feasibility and safety of combined irinotecan chemoembolization and CT-guided high-dose-rate brachytherapy (HDRBT) in patients with unresectable colorectal liver metastases, not specifically studying Alanine.", "results_summary": "The study found significant differences in liver-related blood values (AST, ALT, GGT, hemoglobin) post-therapy, with new grade I/II and III/IV toxicities reported, but all resolved within 3 months without additional treatment. Median local tumor control, PFS, and OS were 6, 4, and 8 months, respectively.", "population_specificity": "23 patients (16 men, 7 women; mean age 70 \u00b1 11.3 years) with unresectable colorectal liver metastases > 3 cm in diameter.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:25.541025+00:00"}
{"study_id": 103694, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine if prolonged intravenous l-arginine administration improves microcirculation and organ function in sepsis patients.", "results_summary": "Prolonged l-arginine administration increased whole-body nitric oxide synthesis but did not improve local perfusion or organ function. The treatment was safe regarding global hemodynamics, though an increase in P (unspecified parameter) was observed.", "population_specificity": "Critically ill patients with septic shock.", "effective_dosage": "1.2 \u03bcmol kg (incomplete dosage information).", "study_duration": "72 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.024984+00:00"}
{"study_id": 103693, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the latest discoveries and controversies regarding enzymes metabolizing methylarginines, including alanine: glyoxylate aminotransferase 2 (AGXT2), and propose novel therapeutic directions.", "results_summary": "The abstract highlights that AGXT2 metabolizes methylarginines but also has cardiovascular protective substrates, making the net effect of targeting AGXT2 unclear. Recent studies have revived interest in this research area.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.427962+00:00"}
{"study_id": 103696, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine the characteristics, prevalence, and treatment outcomes of autoimmune hepatitis (AIH) in patients with HIV, not specifically Alanine.", "results_summary": "The study found that male HIV patients with AIH had significantly higher alanine transaminase levels at diagnosis. Most patients responded well to immunosuppressive treatment, except for a few lost to follow-up or expired.", "population_specificity": "Patients with HIV and autoimmune hepatitis (AIH).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.736454+00:00"}
{"study_id": 103692, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, particularly regarding alanine aminotransferase levels, when administered intermittently with high-frequency dosing in healthy participants.", "results_summary": "The study found that ubrogepant was well tolerated, with no clinically relevant signal of hepatotoxicity. Two cases of alanine aminotransferase increases (possibly or probably related to treatment) were transient, asymptomatic, and resolved with continued dosing.", "population_specificity": "Healthy adults aged 18-50 years.", "effective_dosage": "100 mg (2 \u00d7 50 mg tablets) on 2 consecutive days followed by 2 consecutive days of placebo, alternating for 8 weeks.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.207120+00:00"}
{"study_id": 103697, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to characterize the prevalence and factors associated with advanced liver histology in patients with NAFLD and normal alanine aminotransferase (ALT) levels.", "results_summary": "The study found that 19% of patients had NASH with stage 2-3 fibrosis and 7% had cirrhosis, identifying specific clinical variables associated with these conditions. Prediction models for detecting advanced liver histology showed moderate to high accuracy (AUC 0.70 for NASH F2-3 and 0.85 for cirrhosis).", "population_specificity": "534 adults with biopsy-proven NAFLD and normal ALT/AST levels (<40U/L).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.757167+00:00"}
{"study_id": 103695, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the infection risk and related mortality in patients with noncirrhotic hepatitis C virus (NC-HCV) compared to other groups and assess the impact of antiviral therapy on infection risk.", "results_summary": "The study found that NC-HCV patients had a higher risk of hospitalization for infections, particularly septicemia and lower respiratory, reproductive, and urinary tract infections, but no increased risk of infection-related death. Antiviral therapy significantly reduced infection-related hospitalization and death risks in HCV patients.", "population_specificity": "115,336 adults (mean age 52.2 years; 35.6% men) without cirrhosis, including NC-HCV (n = 2,839), NC-HBV (n = 8,316), and NBNC (n = 104,181) groups.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 8.2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:29.145634+00:00"}
{"study_id": 103698, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the impact of dietary intervention plus nutritional orientation versus nutritional orientation alone on gut microbiota and metabolic-nutritional profiles in patients with non-alcoholic steatohepatitis, including effects on alanine aminotransferase levels.", "results_summary": "The DIET group showed significant reductions in alanine aminotransferase levels (p<0.001) and other metabolic markers, suggesting dietary modifications improve liver health. No significant changes were observed in the control group.", "population_specificity": "40 outpatients with non-alcoholic steatohepatitis (mean age 49.48 \u00b1 10.3 years).", "effective_dosage": "Not specified for alanine; overall diet composition was 1,651.34 \u00b1 263.25 kcal, 25% proteins.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:32.227593+00:00"}
{"study_id": 103700, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers investigated the impact of whole grain wheat consumption on liver and inflammatory resilience, with a focus on changes in alanine aminotransferase levels.", "results_summary": "The study found that whole grain wheat consumption decreased alanine aminotransferase levels postprandially, indicating improved liver resilience, while refined wheat increased inflammatory markers.", "population_specificity": "Overweight and obese men (n=19) and postmenopausal women (n=31) aged 45-70 with mildly elevated plasma cholesterol.", "effective_dosage": "98 g/d of whole grain wheat", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.363776+00:00"}
{"study_id": 103699, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers evaluated the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma, including monitoring alanine aminotransferase levels as an adverse event.", "results_summary": "The study found that pazopanib showed positive drug activity in conventional chondrosarcoma, with a disease control rate of 43% at 16 weeks. Elevated alanine aminotransferase (9%) was among the most common grade 3 or higher adverse events.", "population_specificity": "Patients with unresectable or metastatic conventional chondrosarcoma (any grade), excluding mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes.", "effective_dosage": "800 mg once daily", "study_duration": "28-day cycles (primary endpoint assessed at 16 weeks/4 cycles)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.469333+00:00"}
{"study_id": 103703, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of SGLT2 inhibitors on serum alanine aminotransferase (ALT) levels in patients with type 2 diabetes (T2D).", "results_summary": "The study found that SGLT2 inhibitors significantly reduced ALT levels in T2D patients, particularly in those with elevated baseline ALT levels (>1\u00d7 ULN), showing a mean decrease of -26.5 U/L. Patients with normal baseline ALT levels (\u22641\u00d7 ULN) showed minimal change.", "population_specificity": "Patients with type 2 diabetes (mean age 59.3 years) from Taiwan.", "effective_dosage": "Not specified", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.858971+00:00"}
{"study_id": 103705, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the antifibrotic potential of clinically available vitamin D analogs compared to calcitriol in vitro and in vivo, focusing on liver fibrosis.", "results_summary": "The study examined the effects of vitamin D analogs on murine hepatic stellate cells, Kupffer cells, and human LX-2 cells, as well as in vivo liver fibrosis induced by CCl4, but did not report specific findings related to Alanine.", "population_specificity": "Murine hepatic stellate cells, Kupffer cells, and human LX-2 cells; in vivo liver fibrosis model using CCl4.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.991313+00:00"}
{"study_id": 103704, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare biomarker differences between severe isolated right ventricular (RV) dysfunction and severe isolated left ventricular (LV) dysfunction after cardiac surgery, including alanine transferase levels.", "results_summary": "The study found that patients with severe isolated RV dysfunction had significantly lower preoperative alanine transferase levels compared to those with LV dysfunction (19.3 \u00b1 1.5 vs. 32.7 \u00b1 4.2, p\u202f=\u202f0.001). No other significant findings related to alanine were reported.", "population_specificity": "46 patients with severe isolated RV or LV dysfunction after cardiac surgery.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.232789+00:00"}
{"study_id": 103701, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate potential drug-drug interactions between glecaprevir/pibrentasvir (a treatment for HCV) and various HIV antiretrovirals, including effects on alanine transaminase levels.", "results_summary": "The study found that glecaprevir exposure increased significantly with ritonavir-boosted HIV protease inhibitors, leading to elevated alanine transaminase levels when combined with atazanavir/ritonavir. No clinically significant interactions were observed with other antiretrovirals.", "population_specificity": "Patients coinfected with hepatitis C and human immunodeficiency viruses (HCV; HIV).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "Atazanavir/ritonavir (contraindicated), ritonavir-boosted protease inhibitors and efavirenz (not recommended). No significant interactions with other studied antiretrovirals.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.510558+00:00"}
{"study_id": 103702, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the effects of osimertinib on simvastatin exposure in patients with advanced EGFR-mutated non-small cell lung cancer and liver metastases.", "results_summary": "The study found that two patients with liver metastases and high simvastatin exposure prior to osimertinib treatment experienced changes in simvastatin exposure after osimertinib administration. Both patients had abnormal liver function tests and significant liver metastasis at baseline.", "population_specificity": "Patients with advanced EGFR-mutated non-small cell lung cancer and disease progression post-EGFR tyrosine kinase inhibitor treatment, specifically two patients with liver metastases.", "effective_dosage": "Simvastatin 40 mg (single oral doses on day 1 and day 31), osimertinib 80 mg once daily (days 3-32).", "study_duration": "31 days of continuous osimertinib treatment.", "interactions": "Interaction between osimertinib and simvastatin was noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.524592+00:00"}
{"study_id": 103707, "supplement_id": 863, "safety_score": "70", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the outcomes of stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B who had achieved virological suppression.", "results_summary": "The study found that stopping therapy resulted in sustained disease remission in 29% of patients, compared to 82% in those who continued. However, 33% of patients who stopped therapy experienced relapse, and 38% required retreatment.", "population_specificity": "Patients with chronic hepatitis B who had received nucleos(t)ide analogue therapy for \u22651 year and achieved virological suppression.", "effective_dosage": "Not specified", "study_duration": "72 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:41.947927+00:00"}
{"study_id": 103712, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the efficacy and safety of nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with previously untreated advanced or metastatic renal cell carcinoma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:43.855673+00:00"}
{"study_id": 103709, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were not studying Alanine directly but rather evaluating treatment initiation, time to treatment, and real-world effectiveness of direct-acting antiviral therapy in individuals with hepatitis C virus infection, with high baseline alanine aminotransferase levels noted as a factor negatively associated with treatment initiation.", "results_summary": "The study found that high baseline alanine aminotransferase levels were negatively associated with treatment initiation for hepatitis C virus infection, but it did not assess the effects of Alanine itself.", "population_specificity": "Hepatitis C virus-infected individuals aged >18 years diagnosed with chronic hepatitis C virus infection between January 1, 2014, and December 31, 2015.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.527344+00:00"}
{"study_id": 103710, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to define chronic HBV phenotypes in children using updated population-based upper limit of normal alanine aminotransferase (ALT) levels and compare them with local laboratory ULN, while identifying relationships with host and viral factors.", "results_summary": "The study found that using updated ALT upper limits significantly reduced the proportion of children classified as immune-tolerant (from 35% to 12%) and increased those classified as having chronic hepatitis B (82%). Among HBeAg-negative participants, only 22% were inactive carriers, while 61% had an indeterminate phenotype with abnormal ALT and low HBV DNA levels.", "population_specificity": "Children with chronic HBV infection in the United States and Canada.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.359913+00:00"}
{"study_id": 103708, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Rova-T (an antibody-drug conjugate) in Japanese patients with advanced recurrent small cell lung cancer (SCLC), not specifically Alanine.", "results_summary": "The study found that Rova-T exhibited manageable toxicity in Japanese patients, with common adverse events including decreased platelet count, pleural effusion, and increased alanine aminotransferase. Preliminary efficacy showed a 17% confirmed partial response rate and a disease control rate of 56% in DLL3-high patients.", "population_specificity": "Japanese patients with advanced recurrent SCLC (N=29).", "effective_dosage": "Rova-T (0.2 or 0.3 mg/kg) intravenously on Day 1 of each 6-week cycle for 2 doses, with dexamethasone (8 mg BID oral) on specific days.", "study_duration": "Two 6-week cycles (12 weeks total).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.362009+00:00"}
{"study_id": 103711, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy of vitamin E on clinical outcomes, including alanine transaminase levels, in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Four out of five RCTs in adults showed significant improvements in alanine transaminase and other liver function markers with vitamin E, while only one of four RCTs in children demonstrated similar benefits. Meta-analysis indicated insignificant differences between vitamin E and placebo, though vitamin E slightly improved alanine transaminase and aspartate transaminase levels.", "population_specificity": "Adults and children with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.489405+00:00"}
{"study_id": 103713, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effectiveness of antiviral treatments, including those affecting alanine aminotransferase (ALT) normalization, in chronic hepatitis B (CHB) patients.", "results_summary": "Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) were most effective for virologic response (VR) and ALT normalization in both HBeAg-positive and HBeAg-negative populations, with TAF showing broad efficacy across multiple outcomes.", "population_specificity": "Treatment-na\u00efve adult CHB patients, categorized as HBeAg-positive or HBeAg-negative.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.852969+00:00"}
{"study_id": 103714, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "The researchers aimed to compare the efficacy and safety of two formulations of tenofovir disoproxil fumarate (Qingzhong and Viread) in Chinese patients with chronic hepatitis B (CHB), including the normalization of alanine aminotransferase (ALT) levels.", "results_summary": "Both Qingzhong and Viread showed similar efficacy in reducing HBV DNA levels, achieving viral suppression, normalizing ALT levels, and comparable safety profiles. The rates of HBeAg loss, seroconversion, and HBsAg loss were also similar between the two groups.", "population_specificity": "Chinese patients with chronic hepatitis B (HBeAg-positive and HBeAg-negative).", "effective_dosage": "300 mg once daily.", "study_duration": "48 weeks for initial comparison, followed by Qingzhong administration up to week 240.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:47.511346+00:00"}
{"study_id": 103715, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify predictors of poor response to urate-lowering therapy (ULT) in gout patients, including factors like alanine transaminase levels.", "results_summary": "Higher alanine transaminase levels were associated with poor response to ULT in gout patients, but the study did not focus on alanine's direct effects or efficacy.", "population_specificity": "Patients with hyperuricemia (serum urate level \u2265 8.0 mg/dL) and gout.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:49.388444+00:00"}
{"study_id": 103717, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the harmonization of reference intervals (RIs) for general chemistry analytes, including alanine aminotransferase, across different laboratories and analytical platforms in Hong Kong.", "results_summary": "The study found sufficient inter-laboratory and inter-platform agreement for alanine aminotransferase, but reference intervals were heterogeneous across laboratories, indicating a lack of harmonization in current practices.", "population_specificity": "10 chemical pathology laboratories in Hong Kong using four different analytical platforms.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.109839+00:00"}
{"study_id": 103716, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess liver function deterioration, including changes in alanine transaminase (ALT) levels, after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients.", "results_summary": "The study found that 43% of patients had ALT deterioration in the acute period (\u226429 days post-TACE), and 25% in the chronic period (30-90 days post-TACE), with higher rates in diabetic subgroups.", "population_specificity": "Real-world HCC patients in the US who underwent a single TACE between 2010 and 2016.", "effective_dosage": "Not available", "study_duration": "Acute (\u226429 days) and chronic (30-90 days) post-TACE periods.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.088584+00:00"}
{"study_id": 103718, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of orlistat and liraglutide in reducing weight and improving metabolic markers, including alanine transaminase levels, in patients with overweight or obesity.", "results_summary": "Both drugs significantly reduced alanine transaminase levels, with liraglutide showing greater weight loss and metabolic improvements compared to orlistat. The study did not focus specifically on alanine's effects but noted its reduction as part of broader metabolic changes.", "population_specificity": "Adult patients with BMI \u226530 kg/m\u00b2 and insufficient weight loss after a lifestyle modification program.", "effective_dosage": "Orlistat 120 mg three times daily; liraglutide up to 3 mg daily.", "study_duration": "Median follow-up of 7 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.150937+00:00"}
{"study_id": 103719, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy and safety of IFN-\u03b1 therapy in children with chronic hepatitis B (CHB) and to identify ideal antiviral therapies for this population.", "results_summary": "The study found that IFN-\u03b1 therapy was well tolerated, with only mild adverse effects, and achieved high rates of HBV-DNA negativity (88.9%), HBeAg seroconversion (92.9%), and HBsAg clearance (22.2%) in children with CHB.", "population_specificity": "Children aged >1 year with chronic hepatitis B (CHB) without advanced fibrosis.", "effective_dosage": "IFN \u03b1-2b administered subcutaneously by body surface area (BSA) category, based on 3 MU/m\u00b2.", "study_duration": "Median 48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.477465+00:00"}
